denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Tabachri, M.
Tabanelli, V.
2909 - The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study
4195 - A Digital Gene-Expression Signature Supports Mediastinal Gray Zone Lymphoma Stratification within Classical Hodgkin or Primary Mediastinal B-Cell Lymphoma
4811 - Validation of Argo (Automatic record generator for Onco-Hematology), a New App Supporting the Automatic Conversion of Paper-Based Pathology Reports in Standardized Ecrfs
4195 - A Digital Gene-Expression Signature Supports Mediastinal Gray Zone Lymphoma Stratification within Classical Hodgkin or Primary Mediastinal B-Cell Lymphoma
4811 - Validation of Argo (Automatic record generator for Onco-Hematology), a New App Supporting the Automatic Conversion of Paper-Based Pathology Reports in Standardized Ecrfs
Tabares Gaviria, P.
Tabata, M.
Tabata, R.
Tabatabaeian, H.
Tabayashi, T.
Tabe, Y.
Tabone, M. D.
Taborda, C. C.
Tabuchi, K.
Tabuchi, T.
Tada, Y.
Tadesse, F.
Tadic-Ovcina, M.
Tadmor, T.
345 - Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment – Outcome Results from the CLL13/GAIA Trial
346 - High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1928 - Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.
2743 - Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice – a Prospective Analysis from the Revive Study
3164 - The Involvement of LAG3+ Plasma Cells in the Development of Multiple Myeloma
4058 - Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment – a Real-World Prospective Analysis from the Revive Study Group
4299 - Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era
4444 - Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov-2 Variants in Patients with CLL
346 - High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1928 - Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.
2743 - Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice – a Prospective Analysis from the Revive Study
3164 - The Involvement of LAG3+ Plasma Cells in the Development of Multiple Myeloma
4058 - Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment – a Real-World Prospective Analysis from the Revive Study Group
4299 - Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era
4444 - Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov-2 Variants in Patients with CLL
Tadokoro, J.
Tadros, S.
Tadros, W.
Tafuri, A.
1649 - Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly/FRAIL Patients, with Diffuse Large B-Cell Lymphoma
1785 - The CXCR4dim/CD5bright Proliferative Fraction Reappears in Relapsed CLL Under Ibrutinib, Enriched in BTK Mutations
1789 - An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients in Novel Categories with Different Risk of Early Treatment
1817 - Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence
2895 - Impact of COVID-19 Pandemic Waves on Outcomes of Patients with Previously Untreated Advanced Follicular Lymphoma Enrolled in the Urban Ambispective Study in Italy
1785 - The CXCR4dim/CD5bright Proliferative Fraction Reappears in Relapsed CLL Under Ibrutinib, Enriched in BTK Mutations
1789 - An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients in Novel Categories with Different Risk of Early Treatment
1817 - Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study Evidence
2895 - Impact of COVID-19 Pandemic Waves on Outcomes of Patients with Previously Untreated Advanced Follicular Lymphoma Enrolled in the Urban Ambispective Study in Italy
Taga, T.
605 - Evaluation of High-Dose Cytarabine Induction Therapy and Flow Cytometric Measurable Residual Disease Monitoring for Children with De Novo Acute Myeloid Leukemia: A Report from the JPLSG-AML-12 Trial
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
4114 - Prognosis of Pediatric Acute Myeloid Leukemia with KMT2A-MLLT3 According to DNA Methylation Patterns: Jccg JPLSG AML-05 Study
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
4114 - Prognosis of Pediatric Acute Myeloid Leukemia with KMT2A-MLLT3 According to DNA Methylation Patterns: Jccg JPLSG AML-05 Study
Tagalakis, V.
Tagawa, H.
Taggi Pinto, A.
Tagliaferri, M. A.
3335 - A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
4652 - Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
4652 - Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
Tagliafico, E.
Tagmount, A.
Taher, A. T.
804 - Effect of Luspatercept in β-Thalassemia Patients with β0/β0 Genotype: A Subgroup Analysis of the BELIEVE Study
2349 - A Closer Look at Changes in Hemoglobin Levels in Patients with Non-Transfusion Dependent β-Thalassemia Treated with Luspatercept: Post Hoc Analysis of the Phase 2 BEYOND Trial
3669 - Erythroid Response in Patients with Non-Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Long-Term Data from the BEYOND Trial
3671 - Effect of Luspatercept on Red Blood Cell (RBC) Transfusion Burden, Iron Chelation Therapy (ICT), and Iron Overload in Adults with Transfusion-Dependent β‑Thalassemia (TDT) from the BELIEVE Trial: A Long-Term Analysis
3782 - Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/ Factor VIII Concentrate in Previously Treated Patients with Von Willebrand Disease
2349 - A Closer Look at Changes in Hemoglobin Levels in Patients with Non-Transfusion Dependent β-Thalassemia Treated with Luspatercept: Post Hoc Analysis of the Phase 2 BEYOND Trial
3669 - Erythroid Response in Patients with Non-Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Long-Term Data from the BEYOND Trial
3671 - Effect of Luspatercept on Red Blood Cell (RBC) Transfusion Burden, Iron Chelation Therapy (ICT), and Iron Overload in Adults with Transfusion-Dependent β‑Thalassemia (TDT) from the BELIEVE Trial: A Long-Term Analysis
3782 - Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/ Factor VIII Concentrate in Previously Treated Patients with Von Willebrand Disease
Taherinasab, A.
Tahri, S.
108 - Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy
1818 - Stromal Cell-Activated Bone Marrow Neutrophils Provide BAFF in Newly Diagnosed and Treated Multiple Myeloma
1828 - Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma
4452 - MAF Translocations Are Enriched in NDMM Patients with Elevated Levels of Circulating Tumor Cells Suggesting a Genetic Basis for Aggressive Disease Course
4485 - Single-Cell Transcriptomic Analysis Reveals Reduction of Cytotoxic NK Cells in a Subset of Newly Diagnosed Multiple Myeloma Patients Impacting Outcome after Daratumumab Therapy
1818 - Stromal Cell-Activated Bone Marrow Neutrophils Provide BAFF in Newly Diagnosed and Treated Multiple Myeloma
1828 - Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma
4452 - MAF Translocations Are Enriched in NDMM Patients with Elevated Levels of Circulating Tumor Cells Suggesting a Genetic Basis for Aggressive Disease Course
4485 - Single-Cell Transcriptomic Analysis Reveals Reduction of Cytotoxic NK Cells in a Subset of Newly Diagnosed Multiple Myeloma Patients Impacting Outcome after Daratumumab Therapy
Tai, E. S.
Tai, Y. T.
241 - BRD9 Is Essential for Ribosome Biogenesis and the Survival of Multiple Myeloma Cells
350 - PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment
859 - Identification a Novel Molecular Mechanism Underlying the Anti-CD38-Based Treatment Resistance in Multiple Myeloma Patients
4478 - Γ-Secretase Inhibitors Enhance the Potency of BCMA-Targeting T Cell Engagers Against Multiple Myeloma Cells without Adverse Impact on T-Cell Activation and Differentiation
350 - PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment
859 - Identification a Novel Molecular Mechanism Underlying the Anti-CD38-Based Treatment Resistance in Multiple Myeloma Patients
4478 - Γ-Secretase Inhibitors Enhance the Potency of BCMA-Targeting T Cell Engagers Against Multiple Myeloma Cells without Adverse Impact on T-Cell Activation and Differentiation
Taiclet, S. N.
Tailor, D.
Taing, L.
Takabayashi, Y.
Takagi, M.
Takahashi, H.
Takahashi, H.
Takahashi, K.
95 - Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data
204 - Preclinical Efficacy of Novel Drug Combination Against AML with 3q26 Lesions and EVI1 Overexpression
221 - Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia
619 - Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia
825 - Genome-Wide CRISPR Screen Reveals Dependency of PPM1D-mutant Cells on DNA Repair
858 - Clinical and Biological Effects of Canakinumab in Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Phase 2 Clinical Trial
927 - Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis
1293 - Oncometabolite-Independent Anti-Apoptotic Feature Via Phospholipid Metabolic Adaptation in IDH2 Mutant AML Cells
1756 - RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia
2601 - Efficacy of Novel Non-Chemotherapy Combinations Against AML Cells with Mutant NPM1
2746 - Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
2761 - A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
2805 - The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency
2814 - Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies
3440 - Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial
3889 - Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy
3967 - Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53
4038 - The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms
4059 - A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up
4074 - Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study
204 - Preclinical Efficacy of Novel Drug Combination Against AML with 3q26 Lesions and EVI1 Overexpression
221 - Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia
619 - Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia
825 - Genome-Wide CRISPR Screen Reveals Dependency of PPM1D-mutant Cells on DNA Repair
858 - Clinical and Biological Effects of Canakinumab in Lower-Risk Myelodysplastic Syndromes (MDS): Results from a Phase 2 Clinical Trial
927 - Cancer Chemotherapy Accelerates the Loss of Clonal Diversity in Hematopoietic Stem Cells and Promotes the Convergent Evolution of Therapy-Related Clonal Hematopoiesis
1293 - Oncometabolite-Independent Anti-Apoptotic Feature Via Phospholipid Metabolic Adaptation in IDH2 Mutant AML Cells
1756 - RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia
2601 - Efficacy of Novel Non-Chemotherapy Combinations Against AML Cells with Mutant NPM1
2746 - Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
2761 - A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
2805 - The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency
2814 - Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies
3440 - Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial
3889 - Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy
3967 - Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53
4038 - The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms
4059 - A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up
4074 - Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study
Takahashi, N.
Takahashi, N.
2658 - STAT3 Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor-Resistant Cutaneous T-Cell Lymphoma
3012 - ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
4481 - Hypoxia-Induced Oxidative Stress Promotes Proteasome Inhibitor Resistance Via Upregulation of Heme Oxygenase-1 in Multiple Myeloma
3012 - ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
4481 - Hypoxia-Induced Oxidative Stress Promotes Proteasome Inhibitor Resistance Via Upregulation of Heme Oxygenase-1 in Multiple Myeloma
Takahashi, N.
Takahashi, S.
1390 - Clinical Features of Complex Karyotype in Newly Diagnosed Acute Myeloid Leukemia
4036 - Prognostic Impact of CEBPA bZIP Domain Mutation in Cytogenetically Normal Acute Myeloid Leukemia
4095 - Subclinical Minute FLT3-ITD Clone Can be Detected in Clinically FLT3-ITD-Negative Acute Myeloid Leukemia
4150 - Better Prognosis of Dominant-Negative Type of IKZF1 Deletion in BCR-ABL-positive Adult B-Cell Acute Lymphoblastic Leukemia
4036 - Prognostic Impact of CEBPA bZIP Domain Mutation in Cytogenetically Normal Acute Myeloid Leukemia
4095 - Subclinical Minute FLT3-ITD Clone Can be Detected in Clinically FLT3-ITD-Negative Acute Myeloid Leukemia
4150 - Better Prognosis of Dominant-Negative Type of IKZF1 Deletion in BCR-ABL-positive Adult B-Cell Acute Lymphoblastic Leukemia
Takahashi, S.
Takahashi, Y.
Takahashi, Y.
Takahata, M.
321 - Novel Simple Prognostic Index (NJHSG-PI) Can Effectively Predict Prognosis in Patients with Newly Diagnosed DLBCL : A Real World Analysis across 14 Cancer Centers in Japan
324 - Incidentally Detected Complex Karyotypic Abnormalities in the Bone Marrow Provide a Clue to Diagnosing Intravascular Large B-Cell Lymphoma
2987 - Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma
324 - Incidentally Detected Complex Karyotypic Abnormalities in the Bone Marrow Provide a Clue to Diagnosing Intravascular Large B-Cell Lymphoma
2987 - Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma
Takai, M.
Takamatsu, H.
291 - HLA Class I Allele-Specific Pathology Defines Clinical Manifestations of Immune Aplastic Anemia
756 - Anti-Sars-Cov-2 Antibody and T-Cell Responses Using Deep T-Cell Receptor Immunosequencing after Vaccination Among Healthy Individuals and Patients with Multiple Myeloma or Lymphoma
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
4179 - Humoral Response to the Third-Dose COVID-19 Vaccination in Patients with Hematological Malignancy
756 - Anti-Sars-Cov-2 Antibody and T-Cell Responses Using Deep T-Cell Receptor Immunosequencing after Vaccination Among Healthy Individuals and Patients with Multiple Myeloma or Lymphoma
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
4179 - Humoral Response to the Third-Dose COVID-19 Vaccination in Patients with Hematological Malignancy
Takamatsu, Y.
445 - Clinical Features, Treatment Patterns, and Outcomes Among 837 Patients with Adult T-Cell Leukemia-Lymphoma in the Real-World Setting: A Comparison of Endemic Regions
1614 - Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)
2965 - Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis
1614 - Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)
2965 - Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis
Takao, S.
Takaori-Kondo, A.
Takashima, S.
Takata, K.
Takayama, G.
Takayama, N.
Takeda, A.
Takeda, J.
85 - Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies
202 - CTX-712, a Novel Splicing Modulator Targeting Myeloid Neoplasms
1228 - Distinct Pathogenesis of Clonal Hematopoiesis Revealed By Single Cell RNA Sequencing Integrated with Highly Sensitive Genotyping Method
1750 - Cooperative Effects of SRSF2 and STAG2 mutations on Development of Myelodysplastic Syndrome and Its Related Disorders
202 - CTX-712, a Novel Splicing Modulator Targeting Myeloid Neoplasms
1228 - Distinct Pathogenesis of Clonal Hematopoiesis Revealed By Single Cell RNA Sequencing Integrated with Highly Sensitive Genotyping Method
1750 - Cooperative Effects of SRSF2 and STAG2 mutations on Development of Myelodysplastic Syndrome and Its Related Disorders
Takeda, R.
Takeda, Y.
Takeda, Y.
Takedani, H.
Takeishi, S.
Takemoto, C.
Takeshita, J.
Takeuchi, K.
Takeuchi, M.
Takeuchi, M.
Takeuchi, M.
Takeuchi, M.
Takeyama, K.
Takeyama, M.
Takezaki, M.
Taki, M.
Takiar, R.
Takimoto, C. H.
Takimoto, T.
Takita, J.
Takita, J.
Takizawa, H.
Takizawa, T.
Takrouri, K.
Takubo, K.
Talano, J. A.
2033 - Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults
4662 - Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups
4674 - Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel
4662 - Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups
4674 - Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel
Talasila, S.
Talati, C.
824 - The Long Non-Coding RNA MALAT1 Is Necessary for Hematopoietic Stem and Progenitor Cell Expansion and Preleukemic Myeloproliferation in TET2 Deficient Myeloid Neoplasms
1484 - Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1-Mutated AML
4730 - Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies
1484 - Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1-Mutated AML
4730 - Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies
Talbot, A.
Talbot, L.
Tallack, M.
Tallada, S.
Tallman, M. S.
306 - Characteristics and Prognostic Effects of DNMT3A Co-Mutations
421 - A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 Trial
881 - Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia
1273 - DNA Polymerase Theta Protects Leukemia Cells from Metabolic-Induced DNA Damage
2077 - Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations
LBA-1 - Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial
421 - A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 Trial
881 - Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia
1273 - DNA Polymerase Theta Protects Leukemia Cells from Metabolic-Induced DNA Damage
2077 - Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations
LBA-1 - Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial
Talluri, S.
642 - Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma
1825 - Exonuclease 1 Drives Growth and Genomic Instability in Multiple Myeloma through Interaction with CAD, a Key Protein Involved in De Novo Pyrimidine Biosynthesis
3165 - Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma
4475 - Flap Structure-Specific Endonuclease 1 Coordinates with a Helicase (ASCC3) to Drive Genomic Instability, Proliferation and Poor Clinical Outcome in Myeloma
1825 - Exonuclease 1 Drives Growth and Genomic Instability in Multiple Myeloma through Interaction with CAD, a Key Protein Involved in De Novo Pyrimidine Biosynthesis
3165 - Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma
4475 - Flap Structure-Specific Endonuclease 1 Coordinates with a Helicase (ASCC3) to Drive Genomic Instability, Proliferation and Poor Clinical Outcome in Myeloma
Talotta, D.
Talpaz, M.
238 - Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24
620 - Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
630 - Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib
740 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
1679 - Quantitative MRI Identifies Heterogeneous Bone Marrow Treatment Responses in a Mouse Model of Myelofibrosis
1682 - Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
4344 - Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study
4368 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
620 - Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
630 - Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib
740 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
1679 - Quantitative MRI Identifies Heterogeneous Bone Marrow Treatment Responses in a Mouse Model of Myelofibrosis
1682 - Fedratinib Induces Cytokine Changes Correlating with Clinical Response in Ruxolitinib Exposed Myelofibrosis Patients: Biomarker Analysis from the Freedom Trial
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
4344 - Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study
4368 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses
Talsania, A.
3151 - Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy
3249 - Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma
3249 - Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma
Talucci, S.
Talukdar, S. D.
Tam, C. S.
75 - Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study
347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
2894 - Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis
4241 - A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma – a Bridge to Transplant and an Effective Salvage for the Unfit
4449 - Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD)
347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
2894 - Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis
4241 - A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma – a Bridge to Transplant and an Effective Salvage for the Unfit
4449 - Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD)
Tam, C. S.
92 - Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study
229 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
962 - A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data
3540 - Preliminary Results of Voice (Virtual Opinions poll Independent Centered on CLL patients’ Experience): A Global Survey to Assess the Disease-Specific Knowledge and Perspectives of Real-World Patients with CLL
4201 - A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
LBA-6 - Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
229 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
962 - A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data
3540 - Preliminary Results of Voice (Virtual Opinions poll Independent Centered on CLL patients’ Experience): A Global Survey to Assess the Disease-Specific Knowledge and Perspectives of Real-World Patients with CLL
4201 - A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
LBA-6 - Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study
Tam, D.
Tam, E.
2105 - Impact of FLT3 Inhibitor-Based Therapies on Outcomes of Acute Myeloid Leukemia (AML) Patients Receiving Allogenic Stem Cell Transplantation: A Retrospective Study
4068 - Survival and Outcomes after Relapse in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated with Venetoclax-Based Chemotherapy
4068 - Survival and Outcomes after Relapse in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated with Venetoclax-Based Chemotherapy
Tam, W.
Tamaki, M.
Tamamushi, Y.
Tamaresis, J.
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
Tamari, R.
881 - Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia
2077 - Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations
2092 - Outcomes and Management of Sars-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation (HCT) and CAR-T Therapy
4417 - Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes
4686 - PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)
4767 - Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia
2077 - Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations
2092 - Outcomes and Management of Sars-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation (HCT) and CAR-T Therapy
4417 - Evaluating Stem Cells to Predict Post-Transplant Relapse in the Myelodysplastic Syndromes
4686 - PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)
4767 - Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia
Tamariz-Amador, L. E.
Tamaru, J. I.
Tamayo, J.
Tambaro, F. P. P.
Tamburini, J.
1330 - C/EBPα Confers Dependence to Fatty Acid Biosynthetic Pathways and Vulnerability to Lipid Oxidative Stress in FLT3-Mutant Leukemia
4715 - T Cell Receptor Repertoire Profiling Reveals Breadth of Cellular Responses Against Sars-Cov-2 after Natural Infection and Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients
4715 - T Cell Receptor Repertoire Profiling Reveals Breadth of Cellular Responses Against Sars-Cov-2 after Natural Infection and Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Tamellini, E.
Tamiro, F.
Tampella, G.
Tamura, H.
Tamura, K.
445 - Clinical Features, Treatment Patterns, and Outcomes Among 837 Patients with Adult T-Cell Leukemia-Lymphoma in the Real-World Setting: A Comparison of Endemic Regions
2965 - Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis
2965 - Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis
Tan, B.
Tan, B.
Tan, C.
100 - Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens
251 - Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma
470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
752 - Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
1940 - A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea
2213 - A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
3225 - Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
251 - Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma
470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
752 - Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
1940 - A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea
2213 - A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression
3225 - Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
Tan, E. C. H.
Tan, F.
3172 - LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity
4084 - LP-118, a Selective Bcl-2 Inhibitor with Tuned Bcl-Xl Activity, Causes Myeloid Differentiation and Cell Death in Acute Myeloid Leukemia (AML)
4795 - Targeting Apoptosis with Novel BH3 Mimetics in T-Lineage Acute Lymphoblastic Leukemia
4084 - LP-118, a Selective Bcl-2 Inhibitor with Tuned Bcl-Xl Activity, Causes Myeloid Differentiation and Cell Death in Acute Myeloid Leukemia (AML)
4795 - Targeting Apoptosis with Novel BH3 Mimetics in T-Lineage Acute Lymphoblastic Leukemia
Tan, G. W.
Tan, H. C.
Tan, K.
44 - The Role of GATA2 in Drug Resistance in AML
145 - Transcriptional Rewiring and Therapeutic Resistance in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia
531 - Single-Cell Pan-Cancer Analysis Reveals Treatment Resistance Stem/Progenitor-like Subpopulation in the High-Risk Pediatric Leukemia
717 - Progenitor Sub-Populations in Treatment Resistant T-ALL
718 - Comprehensive Genome Characterization of Childhood T-ALL Links Oncogene Activation Mechanism and Subtypes to Prognosis
1501 - The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia
145 - Transcriptional Rewiring and Therapeutic Resistance in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia
531 - Single-Cell Pan-Cancer Analysis Reveals Treatment Resistance Stem/Progenitor-like Subpopulation in the High-Risk Pediatric Leukemia
717 - Progenitor Sub-Populations in Treatment Resistant T-ALL
718 - Comprehensive Genome Characterization of Childhood T-ALL Links Oncogene Activation Mechanism and Subtypes to Prognosis
1501 - The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia
Tan, K.
2819 - Single-Cell Transcriptomics Reveals Similarity of Aggressive Infant Acute Lymphoblastic Leukemia Cells to Early Hematopoietic Progenitors
3261 - Graft-Versus-Host Disease Induces Immune Dysregulation through Irreversible Damage to Specialized Immune-Interacting Fibroblastic Stromal Cells in Secondary Lymphoid Organs
3261 - Graft-Versus-Host Disease Induces Immune Dysregulation through Irreversible Damage to Specialized Immune-Interacting Fibroblastic Stromal Cells in Secondary Lymphoid Organs
Tan, L. K.
2052 - Haploidentical Hematopoietic Cell Transplantation of Ex Vivo Tcrαβ-Depleted Grafts with CD45RA-Depleted Memory T Cell Add-Back Reduces Chronic Graft-Versus-Host Disease and Results in Favourable Gvhd-Relapse Free Survival: 5-Year Follow-up of 107 Patients Treated in a Multicenter Study in Singapore
3386 - Sequential Use of Flamsa, FLAG, CLAG or TEC-Based Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasia Patients: 15 Year Follow-up of the Multicenter Study in Singapore
4711 - Haploidentical Transplant Using Selective Ex-Vivo Tcrαβ Depleting and Memory T Cell Add-Back Results in More Favorable Gvhd-Free /Relapse Free Survival (GRFS) As Compared to Post-Transplant Cyclophosphamide for Adults with Hematological Malignancies - a Comparative Analysis of 170 Patients in a Multicenter Study in Singapore
3386 - Sequential Use of Flamsa, FLAG, CLAG or TEC-Based Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasia Patients: 15 Year Follow-up of the Multicenter Study in Singapore
4711 - Haploidentical Transplant Using Selective Ex-Vivo Tcrαβ Depleting and Memory T Cell Add-Back Results in More Favorable Gvhd-Free /Relapse Free Survival (GRFS) As Compared to Post-Transplant Cyclophosphamide for Adults with Hematological Malignancies - a Comparative Analysis of 170 Patients in a Multicenter Study in Singapore
Tan, L.
Tan, M.
750 - Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
965 - NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
2663 - Bruton’s Tyrosine Kinase (BTK) Degrader Nx-2127 Exhibits Lethal Activity and Synergy with Venetoclax and BET Protein Inhibitor Against MCL Cells Sensitive or Resistant to Covalent BTK Inhibitors
965 - NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
2663 - Bruton’s Tyrosine Kinase (BTK) Degrader Nx-2127 Exhibits Lethal Activity and Synergy with Venetoclax and BET Protein Inhibitor Against MCL Cells Sensitive or Resistant to Covalent BTK Inhibitors
Tan, M.
Tan, M. M.
21 - Do Children with Immune Thrombocytopenia Have Cerebral Microbleeds?
915 - CD8+ TEMRA Clones Cause Platelet Lysis in Immune Thrombocytopenia
1134 - Characterisation of Platelet Sensitivity in Immune Thrombocytopenia Identifies Distinct Subgroups with Either Higher or Lower Platelet Sensitivity
2444 - Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Immune Thrombocytopaenia: a Multi-Centre Review
2451 - Eltrombopag Causes Cell Cycle Arrest of T Cells through Iron Chelation and Could Modulate the Immune Response in ITP
915 - CD8+ TEMRA Clones Cause Platelet Lysis in Immune Thrombocytopenia
1134 - Characterisation of Platelet Sensitivity in Immune Thrombocytopenia Identifies Distinct Subgroups with Either Higher or Lower Platelet Sensitivity
2444 - Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Immune Thrombocytopaenia: a Multi-Centre Review
2451 - Eltrombopag Causes Cell Cycle Arrest of T Cells through Iron Chelation and Could Modulate the Immune Response in ITP
Tan, M.
Tan, M. T.
Tan, P. T.
1443 - Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
4571 - A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
4571 - A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
Tan, S. H.
Tan, S. Y.
1443 - Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
1456 - High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
3656 - Effects of Ker-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes
4361 - Modulation of TGF-β Superfamily Signaling to Treat Myelofibrosis and Mitigate JAK Inhibitor Toxicity: A Report on the Phase 2 Study of Ker-050 in Participants with Myelofibrosis
1456 - High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
3656 - Effects of Ker-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes
4361 - Modulation of TGF-β Superfamily Signaling to Treat Myelofibrosis and Mitigate JAK Inhibitor Toxicity: A Report on the Phase 2 Study of Ker-050 in Participants with Myelofibrosis
Tan, S.
Tan, T. Z.
Tan, T. K.
Tan, X.
1458 - Is Disease Response a Patient-Centered Clinical Trial Endpoint in Acute Myeloid Leukemia: Differences in Symptom Burden and Physical Function By Response Status in the Beat-AML Master Trial
2946 - A Pilot Study Evaluating Acalabrutinib for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphomas
2946 - A Pilot Study Evaluating Acalabrutinib for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphomas
Tan, Y. X.
Tanabe, M.
Tanabe, P.
Tanaguchi, R.
Tanaka, H.
1120 - Platelet-Derived Microvesicles Promote Selective Cell Viability in Hepatocellular Carcinoma: Differences in Properties between Normal Platelets and Tumor Educated Platelets
2435 - Bioprotective Role of Platelet-Derived Microvesicles in Hypothermia: Insights from the Differential Characteristics of Peripheral and Splenic Platelets
2435 - Bioprotective Role of Platelet-Derived Microvesicles in Hypothermia: Insights from the Differential Characteristics of Peripheral and Splenic Platelets
Tanaka, H.
Tanaka, J.
Tanaka, K. L.
Tanaka, M.
368 - Indirectly Recognizable Epitopes Derived from Recipient Mismatched HLA-B Are Associated with Adverse Prognosis in Single-Unit Cord Blood Transplantation
876 - The Novel Scoring System to Personalize the Conditioning Intensity in Elderly Patients
2053 - Novel Prediction Models of Nonrelapse Mortality in Patients Specific to Each Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Analysis from the Kanto Study Group for Cell Therapy (KSGCT)
2687 - Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL : JALSG Ph+ALL TKI- SCT Study
4755 - Donor Selection Considering Donor Age in Hematopoietic Cell Transplant Recipients 50-75 Years of Age
876 - The Novel Scoring System to Personalize the Conditioning Intensity in Elderly Patients
2053 - Novel Prediction Models of Nonrelapse Mortality in Patients Specific to Each Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Analysis from the Kanto Study Group for Cell Therapy (KSGCT)
2687 - Poor Prognostic Combination of Additional Chromosomal Abnormalities in Ph + ALL : JALSG Ph+ALL TKI- SCT Study
4755 - Donor Selection Considering Donor Age in Hematopoietic Cell Transplant Recipients 50-75 Years of Age
Tanaka, N.
Tanaka, N.
Tanaka, S.
605 - Evaluation of High-Dose Cytarabine Induction Therapy and Flow Cytometric Measurable Residual Disease Monitoring for Children with De Novo Acute Myeloid Leukemia: A Report from the JPLSG-AML-12 Trial
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
Tanaka, Y.
Tanaka, Y.
Tanasi, I.
1017 - Thrombotic and Infectious Complications in Patients with Autoimmune Hemolytic Anemia: A Multicenter Observational Study
3088 - Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
4048 - BCL-2 and BCL-XL Antagonists for the Treatment of Relapsed and Refractory Adult Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. a Campus ALL Real-Life Study
3088 - Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
4048 - BCL-2 and BCL-XL Antagonists for the Treatment of Relapsed and Refractory Adult Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. a Campus ALL Real-Life Study
Tandoh, T.
Tandon, M.
Tandra, A.
Taneja, A.
58 - Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes in Intermediate Risk Cytogenetic Acute Myeloid Leukemia
2262 - The Age, Comorbidities and Albumin (ACA) Index Is Independently Associated with Overall Survival in Patients with Mantle Cell Lymphoma (MCL)
2267 - Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis
2496 - Impact of Race on the Mortality of Thrombotic Thrombocytopenic Purpura in the United States: A Population Study
4506 - A Retrospective Study of Antibody Titers in Patients with Plasma Cell Disorders
2262 - The Age, Comorbidities and Albumin (ACA) Index Is Independently Associated with Overall Survival in Patients with Mantle Cell Lymphoma (MCL)
2267 - Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis
2496 - Impact of Race on the Mortality of Thrombotic Thrombocytopenic Purpura in the United States: A Population Study
4506 - A Retrospective Study of Antibody Titers in Patients with Plasma Cell Disorders
Tang, A.
Tang, A. Y.
Tang, B.
1759 - A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome
3797 - Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study
3797 - Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study
Tang, B.
1509 - Prognostic Significance of Epigenetic Modifiers Gene Mutations in Adult Acute Lymphoblastic Leukemia at Diagnosis
2830 - Metabolic Feature Profiling and Metabolic Vulnerability Targeting in B-Cell Lymphoblastic Leukemia
4149 - Dynamics of Minimal Residual Disease Defines a Novel Risk-Classification and the Role of Allo-HSCT in Adult Ph-Negative B Cell Acute Lymphoblastic Leukemia
2830 - Metabolic Feature Profiling and Metabolic Vulnerability Targeting in B-Cell Lymphoblastic Leukemia
4149 - Dynamics of Minimal Residual Disease Defines a Novel Risk-Classification and the Role of Allo-HSCT in Adult Ph-Negative B Cell Acute Lymphoblastic Leukemia
Tang, C. H.
Tang, D.
1698 - Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study
2312 - The Use of Fedratinib for Myelofibrosis As a Potential Bridge to Hematopoietic Stem Cell Transplantation after Ruxolitinib Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptom, and Hematologic Response
4329 - Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)
2312 - The Use of Fedratinib for Myelofibrosis As a Potential Bridge to Hematopoietic Stem Cell Transplantation after Ruxolitinib Failure: Real-World Assessment of Treatment Characteristics and Spleen, Symptom, and Hematologic Response
4329 - Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)
Tang, G. H.
3804 - The Empower Study – Design of a Randomized Clinical Trial to Assess the Efficacy and Safety of a Plasma-Derived Von Willebrand Factor / Factor VIII Concentrate for Heavy Menstrual Bleeding in Women with Von Willebrand Disease
4843 - Isolated Thrombocytopenia in Older Adults Is Associated with the Diagnosis of Hematologic Malignancy: A Population-Based Study
4843 - Isolated Thrombocytopenia in Older Adults Is Associated with the Diagnosis of Hematologic Malignancy: A Population-Based Study
Tang, G.
61 - Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
115 - Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant
1376 - Outcomes of Patients with B-ALL with Concomitant BCR::ABL1 and CRLF2 Rearrangements
1564 - Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma
2790 - Single Cell RNA-Seq Reveals Intra-Tumoral Heterogeneity Relevant to Differentiation States and Outcomes Among Newly Diagnosed Acute Myeloid Leukemia Patients
2805 - The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency
115 - Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant
1376 - Outcomes of Patients with B-ALL with Concomitant BCR::ABL1 and CRLF2 Rearrangements
1564 - Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma
2790 - Single Cell RNA-Seq Reveals Intra-Tumoral Heterogeneity Relevant to Differentiation States and Outcomes Among Newly Diagnosed Acute Myeloid Leukemia Patients
2805 - The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency
Tang, H.
Tang, H.
Tang, H.
Tang, H.
Tang, J. L.
Tang, K.
1290 - Investigation of Impact Induced By AML1-ETO on Self-Renewal and Differentiation of Hematopoietic Stem and Progenitor Cells in Pre-Leukemic Stage
1419 - Construction of Dual- and Enhanced Dual-Antibodies Targeting CD19 in the Treatment of B-ALL and Investigation of the Relevant Mechanisms
1980 - Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells
3295 - The Investigation of Antitumor Effect of Humanized Bispecific BCMA/CD38 CAR-T Cells on Multiple Myeloma
1419 - Construction of Dual- and Enhanced Dual-Antibodies Targeting CD19 in the Treatment of B-ALL and Investigation of the Relevant Mechanisms
1980 - Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells
3295 - The Investigation of Antitumor Effect of Humanized Bispecific BCMA/CD38 CAR-T Cells on Multiple Myeloma
Tang, K.
Tang, L.
Tang, L.
Tang, L.
257 - Autophagy Facilitates Cancer-Intrinsic Evasion of CAR T Cell-Mediated Cytotoxicity in B-Cell Malignancies
1998 - Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study
2007 - Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies
3286 - Multi-Omics Reveal Plasma Molecular Signatures of B-ALL Patients during CAR-T Cell Therapy
4626 - BTK Inhibitors Improve CART19 Cell Therapy By Modulating Immune System
4636 - Single-Cell Profiling Reveals Contribution of IFITM1 Expression to Severe CRS in CAR-T-Treated B-ALL
1998 - Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study
2007 - Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies
3286 - Multi-Omics Reveal Plasma Molecular Signatures of B-ALL Patients during CAR-T Cell Therapy
4626 - BTK Inhibitors Improve CART19 Cell Therapy By Modulating Immune System
4636 - Single-Cell Profiling Reveals Contribution of IFITM1 Expression to Severe CRS in CAR-T-Treated B-ALL
Tang, M. W.
1426 - Comparison of Hidac Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Study
4700 - Improved T-Cell Chimerism and Successful Withdrawal of Immunosuppression after Non-Myeloablative Stem Cell Transplantation for Sickle Cell Disease with Azathioprine/Hydroxyurea Preconditioning Added to Alemtuzumab/TBI Conditioning
4700 - Improved T-Cell Chimerism and Successful Withdrawal of Immunosuppression after Non-Myeloablative Stem Cell Transplantation for Sickle Cell Disease with Azathioprine/Hydroxyurea Preconditioning Added to Alemtuzumab/TBI Conditioning
Tang, S.
Tang, T.
Tang, W.
Tang, W.
Tang, X. Y.
267 - Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel or Other Donor Sources in Patients with Hematologic Malignancies: Comparison of Clinical Trial Results to Center for International Blood and Marrow Transplant Research Database Controls
571 - A Real-World Evidence Comparison of 1-Year Overall Survival and Relapse-Free Survival between Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Versus Antithymocyte Globulin or Post-Transplant Cyclophosphamide Following Allogeneic Hematopoietic Cell Transplantation
665 - Improved Outcomes of UM171-Expanded Cord Blood Transplantation Compared with Other Graft Sources: Real World Evidence
571 - A Real-World Evidence Comparison of 1-Year Overall Survival and Relapse-Free Survival between Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Versus Antithymocyte Globulin or Post-Transplant Cyclophosphamide Following Allogeneic Hematopoietic Cell Transplantation
665 - Improved Outcomes of UM171-Expanded Cord Blood Transplantation Compared with Other Graft Sources: Real World Evidence
Tang, X.
601 - Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial
4146 - Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia
4647 - Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1-like Acute Lymphoblastic Leukemia
4146 - Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia
4647 - Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1-like Acute Lymphoblastic Leukemia
Tang, X.
18 - Secreted Sars-Cov-2 Encoded ORF8 Protein Stimulates Pro-Inflammatory Cytokines and Predicts Severe Clinical Outcome
70 - IRF4 Shapes the Tumor Microenvironment of Follicular Lymphoma
1240 - Increased Tumor-Associated CD66b+ Myeloid-Derived Suppressor Cells in Waldenstrom Macroglobulinemia Inhibit T-Cell Immune Function
70 - IRF4 Shapes the Tumor Microenvironment of Follicular Lymphoma
1240 - Increased Tumor-Associated CD66b+ Myeloid-Derived Suppressor Cells in Waldenstrom Macroglobulinemia Inhibit T-Cell Immune Function
Tang, Y.
Tang, Z.
Tani, M.
737 - Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study
2905 - How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia
4202 - Safety and Efficacy of Parsaclisib in Combination with Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma: Analysis of a Phase 1 Dose-Finding Study (CITADEL‑112)
2905 - How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia
4202 - Safety and Efficacy of Parsaclisib in Combination with Rituximab, Bendamustine + Rituximab, or Ibrutinib in Patients with Previously Treated B-Cell Lymphoma: Analysis of a Phase 1 Dose-Finding Study (CITADEL‑112)
Tanigawara, Y.
Taniguchi, Y.
Tankala, D.
Tankersley, C.
Tannenbaum, A.
Tanner, L.
Tanner, M. R.
115 - Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant
4751 - Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience
4751 - Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience
Tannoury, M.
Tannuri, R. K. K.
Tanosaki, R.
Tanoue, Y.
Tanous, O.
Tanskanen, T.
Tantawy, S. I.
Tantiworawit, A.
917 - Improvement of Platelet Count after Helicobacter Pylori Screening and Eradication in Immune Thrombocytopenia Patients: A Randomized Open-Label Study
1032 - Plasma Metabolomic Profiles Are Imbalanced in Adults Thalassemia Patients with Malnutrition and That Imbalance Is Alleviated By Oral Nutritional Supplements: A Prospective Randomized Controlled Trial
3815 - Profiling of Heparin-Induced Thrombocytopenia Antibodies in Thai People Who Received ChAdOx1 Ncov-19 Vaccination
4300 - Efficacy and Safety of Intravenous Chimeric Antigen Receptor T-Cell Therapy in Adults with Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis
1032 - Plasma Metabolomic Profiles Are Imbalanced in Adults Thalassemia Patients with Malnutrition and That Imbalance Is Alleviated By Oral Nutritional Supplements: A Prospective Randomized Controlled Trial
3815 - Profiling of Heparin-Induced Thrombocytopenia Antibodies in Thai People Who Received ChAdOx1 Ncov-19 Vaccination
4300 - Efficacy and Safety of Intravenous Chimeric Antigen Receptor T-Cell Therapy in Adults with Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis
Tantravahi, S. K.
562 - Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A National Analysis of Overall Survival and Demographic Features
624 - Racial and Ethnic Disparities in Survival Outcomes in Chronic Myeloid Leukemia
1691 - Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study
1734 - A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naïve Myelofibrosis
1765 - Concerto (NCT04409639): A Phase 2 Trial of Cobimetinib in Newly Diagnosed and HMA-Treated CMML Patients with RAS Pathway Mutations
2318 - Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores
3010 - Trends in Frontline Treatment and Overall Survival in the Era of Targeted Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
3011 - Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study
624 - Racial and Ethnic Disparities in Survival Outcomes in Chronic Myeloid Leukemia
1691 - Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study
1734 - A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naïve Myelofibrosis
1765 - Concerto (NCT04409639): A Phase 2 Trial of Cobimetinib in Newly Diagnosed and HMA-Treated CMML Patients with RAS Pathway Mutations
2318 - Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores
3010 - Trends in Frontline Treatment and Overall Survival in the Era of Targeted Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia
3011 - Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study
Tanzer, J. R.
Tanzi, E.
Tao, C.
195 - Single Cell Analysis Highlights Th17-Polarized CD4+ Naive T Cells with JAK3/STAT3 Pathway Activation in Pediatric Severe Aplastic Anemia
816 - Multi-Omics Analysis of Human Mesenchymal Stem Cell Guides Perinatal MSC Based Cellular Therapy for Splenectomy-Nonresponsive Refractory Immune Thrombocytopenia: A Phase I Clinical Trial
1288 - PHF6 Maintains Acute Myeloid Leukemia Via Regulating NF-Κappab Signaling Pathway
816 - Multi-Omics Analysis of Human Mesenchymal Stem Cell Guides Perinatal MSC Based Cellular Therapy for Splenectomy-Nonresponsive Refractory Immune Thrombocytopenia: A Phase I Clinical Trial
1288 - PHF6 Maintains Acute Myeloid Leukemia Via Regulating NF-Κappab Signaling Pathway
Tao, M.
TAO, R.
Tao, W.
Tao, X.
Tapia, D. N.
Tapia, G.
Tapper, W. J.
Tarabadkar, E. S.
Tarallo, M. C.
Taranath, R.
Tarango, C.
Tarantelli, C.
Tarantino, D.
Tarantino, G.
Tarantino, G.
Tarantino, M. D.
2502 - Hereditary Antithrombin Deficiency Pilot Project Registry from the American Thrombosis and Hemostasis Network (ATHN)
3798 - Joint Status and Bleeding Phenotype Characterization in Severe and Non-Severe Hemophilia a and B
3835 - Atenativ, a Plasma-Derived Antithrombin Concentrate, Used in Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Parturition: Study Description (NCT04918173)
3798 - Joint Status and Bleeding Phenotype Characterization in Severe and Non-Severe Hemophilia a and B
3835 - Atenativ, a Plasma-Derived Antithrombin Concentrate, Used in Patients with Congenital Antithrombin Deficiency Undergoing Surgery or Parturition: Study Description (NCT04918173)
Tarantolo, S. R.
Tarasco, E.
Tarasev, M.
Tarawah, A.
1149 - Driving Change: Improving Diagnosis and Awareness of Heavy Menstrual Bleeding and Bleeding Disorders in Women and Girls Among Healthcare Providers
2249 - Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
2249 - Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
Tardivel, A.
Tardivel, A.
Tareen, S.
Tarín Arzaga, L. D. C.
Tarin-Arzaga, L.
Tario, Jr., J. D.
Tarlac, V.
Tarlock, K.
1472 - Clinical and Functional Implications of MYC Variants As a New Class of Pathogenic Variants in AML
4031 - Clinical Outcome and Treatment-Related Mortality in Patients with Acute Myeloid Leukemia Treated at the Uganda Cancer Institute
- The Evolution of Targeted Therapy in Pediatric AML: Small Molecule Inhibitors and Immunotherapeutic Strategies
4031 - Clinical Outcome and Treatment-Related Mortality in Patients with Acute Myeloid Leukemia Treated at the Uganda Cancer Institute
- The Evolution of Targeted Therapy in Pediatric AML: Small Molecule Inhibitors and Immunotherapeutic Strategies
Tarrant, T.
Tartari, C. J.
Tarte, K.
2878 - Sub-Cutaneous Administration of Rituximab Triggers a Pro-Phagocytic Phenotype of Monocytic Compartment in Low-Tumor Burden Follicular Lymphoma Patients Included in the Flirt Clinical Trial, a Lysa Study
3879 - Periosteal Skeletal Stem Cells Can Migrate into the Bone Marrow and Support Hematopoietic Regeneration
3879 - Periosteal Skeletal Stem Cells Can Migrate into the Bone Marrow and Support Hematopoietic Regeneration
Tarzia, C.
Tashiro, H.
Tashiro, H.
Tashkandi, H.
Tasian, S. K.
145 - Transcriptional Rewiring and Therapeutic Resistance in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia
1416 - Non-Canonical Exon Usage in Pediatric Leukemia: Implications for Chemoresistance
1514 - Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition
1516 - Preclinical In Vivo Activity of the Menin Inhibitor Ziftomenib (KO-539) in Pediatric KMT2A-Rearranged Acute Lymphoblastic Leukemia
2725 - A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations
2747 - Clinical Experience with Azacitidine and Venetoclax +/- Gemtuzumab in Pediatric Patients with Relapsed or Refractory Acute Leukemias: A Report from the Children’s Hospital of Philadelphia
2762 - Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial
4621 - Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway
- Clinical Screening for Ph-like ALL and the Developing Role of TKIs
1416 - Non-Canonical Exon Usage in Pediatric Leukemia: Implications for Chemoresistance
1514 - Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition
1516 - Preclinical In Vivo Activity of the Menin Inhibitor Ziftomenib (KO-539) in Pediatric KMT2A-Rearranged Acute Lymphoblastic Leukemia
2725 - A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations
2747 - Clinical Experience with Azacitidine and Venetoclax +/- Gemtuzumab in Pediatric Patients with Relapsed or Refractory Acute Leukemias: A Report from the Children’s Hospital of Philadelphia
2762 - Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial
4621 - Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway
- Clinical Screening for Ph-like ALL and the Developing Role of TKIs
Taskinen, M.
Tassi, I.
Tassone, P.
Tast, B.
Tat, C.
Tatarczuch, M.
Tatarelli, C.
Tatarian, J.
Tate, C.
Tate, J. L.
Tateishi, K.
Tateishi, U.
Tatsumi, K.
Tatsuoka, C.
Tatterton, D.
Taur, Y.
Taurelle, J.
Taurisano, B.
Tausch, E.
343 - Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
345 - Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment – Outcome Results from the CLL13/GAIA Trial
346 - High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
633 - Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome
1359 - Novel BTK Mutations Conferring Resistance to Non-Covalent BTK Inhibitors and Alternative Treatment Strategy
1784 - NOTCH1 Signaling Is Dysregulated in CLL By the Deubiquitinase USP28 That Is Recurrently Affected By Del(11q) and Can be Therapeutically Targeted
1787 - Longitudinal Omics Data Followed By Preclinical Treatment Studies Identify Proteasome Inhibition As Effective Therapy for Ibrutinib-Resistant Chronic Lymphocytic Leukemia
4419 - Proteogenomic Analysis of SF3B1mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways
4436 - Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
345 - Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment – Outcome Results from the CLL13/GAIA Trial
346 - High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
633 - Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome
1359 - Novel BTK Mutations Conferring Resistance to Non-Covalent BTK Inhibitors and Alternative Treatment Strategy
1784 - NOTCH1 Signaling Is Dysregulated in CLL By the Deubiquitinase USP28 That Is Recurrently Affected By Del(11q) and Can be Therapeutically Targeted
1787 - Longitudinal Omics Data Followed By Preclinical Treatment Studies Identify Proteasome Inhibition As Effective Therapy for Ibrutinib-Resistant Chronic Lymphocytic Leukemia
4419 - Proteogenomic Analysis of SF3B1mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways
4436 - Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
Taussig, D.
Taussig, D.
Taussig, D. C.
2757 - Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial
2768 - EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Preliminary Results of an Ongoing Phase I/IIa First in Human Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia
4063 - Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease – Real-World Data from a UK-Wide Programme
2768 - EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Preliminary Results of an Ongoing Phase I/IIa First in Human Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia
4063 - Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease – Real-World Data from a UK-Wide Programme
Tavares, L. P.
Tavenner, M.
Taveras Alam, S.
Tavernari, L.
Tavernier, E.
985 - Dose of IV Busulfan in Reduced Toxicity Conditioning Regimen for Older and/or Frail Patients with AML or MDS
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
Tavian, M.
Tavitian, S.
1405 - Optimizing the Supportive Care of Intensive Chemotherapy in AML : Impact of Vitamin C and D Supplementation in Patients with NPM1 Mutation. a Dataml Registry Study
4347 - Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group
LBA-2 - Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III APPLY-PNH Study
4347 - Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group
LBA-2 - Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III APPLY-PNH Study
Tavor, S.
2743 - Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice – a Prospective Analysis from the Revive Study
4058 - Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment – a Real-World Prospective Analysis from the Revive Study Group
4058 - Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment – a Real-World Prospective Analysis from the Revive Study Group
Tavosanis, A.
Tawaga, S.
Tawana, K.
Tawara, I.
Tawfiq, R. K.
Taxter, T. J.
Tay, Y.
Taylor, A.
Taylor, A.
Taylor, A. M.
Taylor, A.
Taylor, B.
Taylor, G. P.
Taylor, J. G.
Taylor, J. A.
Taylor, J.
45 - XPO1 Overexpression Is a Mechanism of Resistance to Eprenetapopt and 5-Azacitidine Therapy That Can be Therapeutically Exploited for the Treatment of TP53 Mutated Myeloid Malignancies
750 - Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
862 - Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
1434 - Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy
3063 - Splicing Modulators Impair DNA Damage Response and Induce Killing of Cohesin-Mutant MDS/AML
4083 - A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes
4438 - Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton’s Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation
- AMFDP
- Blood Drop: ASH-Harold Amos Medical Faculty Development Program (AMFDP)
750 - Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
862 - Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
1434 - Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy
3063 - Splicing Modulators Impair DNA Damage Response and Induce Killing of Cohesin-Mutant MDS/AML
4083 - A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes
4438 - Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton’s Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation
- AMFDP
- Blood Drop: ASH-Harold Amos Medical Faculty Development Program (AMFDP)
Taylor Meadows, K.
Taylor, M.
Taylor, R. P.
Taylor, S.
Taylor, S.
Taylor, T.
Taylor, Z.
Taylor-Weiner, A.
Tazearslan, C.
Tazón, B.
Tbakhi, A.
266 - Outcome of Haematopoietic Cell Transplantation in 813 Children with Fanconi Anaemia: A Study on Behalf of the EBMT Severe Aplastic Anaemia Working Party and Paediatric Disease Working Party
776 - Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study
2057 - Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study
2576 - HLA-Haploidentical Stem Cell Transplantation in Children with Inherited Bone Marrow Failure Syndromes: A Retrospective Analysis on Behalf of EBMT Severe Aplastic Anemia Working Party
776 - Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study
2057 - Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study
2576 - HLA-Haploidentical Stem Cell Transplantation in Children with Inherited Bone Marrow Failure Syndromes: A Retrospective Analysis on Behalf of EBMT Severe Aplastic Anemia Working Party
Tchkonia, T.
te Boome, L.
te Boome, L.
Te Kronnie, G.
Te Raa, D.
Teachey, D. T.
411 - Rare Deleterious TCF3 Germline Variants and Predisposition to Acute Lymphoblastic Leukemia in Children
531 - Single-Cell Pan-Cancer Analysis Reveals Treatment Resistance Stem/Progenitor-like Subpopulation in the High-Risk Pediatric Leukemia
716 - A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease
717 - Progenitor Sub-Populations in Treatment Resistant T-ALL
718 - Comprehensive Genome Characterization of Childhood T-ALL Links Oncogene Activation Mechanism and Subtypes to Prognosis
1501 - The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia
2411 - Quantification of Neutrophil Extracellular Traps (NETs) in Pediatric Patients with COVID-19 and Multisystem Inflammatory Syndrome (MIS-C) through Plasma and Peripheral Smear Analysis
2825 - RPPA-Profiling in Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia Identifies Protein Patterns Associated with Outcome
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
3733 - Analysis of Clinical Cytokine Panel Profiles As Diagnostic and Prognostic Biomarkers in Pediatric Hyperinflammatory Conditions
4138 - High Immunoproteasome Expression As Indicator for Sensitivity to Bortezomib-Containing Chemotherapy in Newly Diagnosed, Standard and Intermediate Risk, T-Cell Acute Lymphoblastic Leukemia Patients from Children’s Oncology Group Trial AALL1231
4621 - Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway
531 - Single-Cell Pan-Cancer Analysis Reveals Treatment Resistance Stem/Progenitor-like Subpopulation in the High-Risk Pediatric Leukemia
716 - A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease
717 - Progenitor Sub-Populations in Treatment Resistant T-ALL
718 - Comprehensive Genome Characterization of Childhood T-ALL Links Oncogene Activation Mechanism and Subtypes to Prognosis
1501 - The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia
2411 - Quantification of Neutrophil Extracellular Traps (NETs) in Pediatric Patients with COVID-19 and Multisystem Inflammatory Syndrome (MIS-C) through Plasma and Peripheral Smear Analysis
2825 - RPPA-Profiling in Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia Identifies Protein Patterns Associated with Outcome
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
3733 - Analysis of Clinical Cytokine Panel Profiles As Diagnostic and Prognostic Biomarkers in Pediatric Hyperinflammatory Conditions
4138 - High Immunoproteasome Expression As Indicator for Sensitivity to Bortezomib-Containing Chemotherapy in Newly Diagnosed, Standard and Intermediate Risk, T-Cell Acute Lymphoblastic Leukemia Patients from Children’s Oncology Group Trial AALL1231
4621 - Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway
Tear, A.
Teawtrakul, N.
Tebaldi, T.
Tedeschi, A.
92 - Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study
234 - Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial
641 - The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström’s Macroglobulinemia
2905 - How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia
4201 - A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data
234 - Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial
641 - The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström’s Macroglobulinemia
2905 - How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia
4201 - A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with Non-Hodgkin Lymphoma (NHL) or Waldenström Macroglobulinemia (WM): Preliminary Data
Tedone, E.
Tee, T.
Teegavarapu, P. S.
2692 - Inferior Outcome in Non-Adult Young Adolescent B-Cell Acute Lymphoblastic Leukemia Exhibiting Obesity
2723 - Specific Nucleotide Substitutions and Stressors Erode Highly Conserved Genomic Regions in Acute Myelogenous Leukemia
3617 - Predictors of Inferior Survival in African American Patients with Diffuse Large B-Cell Lymphoma
4028 - A Real-World Single-Institution Experience with Hypomethylating Agents Plus BCL-2 Inhibitor for the Treatment of Acute Myeloid Leukemia
4070 - Dexamethasone during Leukemia Induction Therapy to Reduce Incidence of Acute Myelogenous Leukemia Relapse
4111 - Uncovering Ethnic Genomic Disparities Associated with Inferior Outcome in African Americans Diagnosed with Acute Myelogenous Leukemia
2723 - Specific Nucleotide Substitutions and Stressors Erode Highly Conserved Genomic Regions in Acute Myelogenous Leukemia
3617 - Predictors of Inferior Survival in African American Patients with Diffuse Large B-Cell Lymphoma
4028 - A Real-World Single-Institution Experience with Hypomethylating Agents Plus BCL-2 Inhibitor for the Treatment of Acute Myeloid Leukemia
4070 - Dexamethasone during Leukemia Induction Therapy to Reduce Incidence of Acute Myelogenous Leukemia Relapse
4111 - Uncovering Ethnic Genomic Disparities Associated with Inferior Outcome in African Americans Diagnosed with Acute Myelogenous Leukemia
Teer, J.
Tees, M.
965 - NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
3114 - Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study
3114 - Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study
Teets, E. M.
Tefferi, A.
537 - Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy
1402 - Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
1403 - Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms
1715 - Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013
2806 - Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms
3056 - Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome
3086 - Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4064 - Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)
4321 - Differential Impact on Survival in Myeloid Neoplasm Patients with U2AF1 Mutations
4350 - Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
4362 - CPX-351 for Blast-Phase Myeloproliferative Neoplasm (MPN-BP): Mayo Clinic Experience in 10 Consecutive Patients
4375 - Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
1402 - Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
1403 - Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms
1715 - Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013
2806 - Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms
3056 - Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome
3086 - Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4064 - Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)
4321 - Differential Impact on Survival in Myeloid Neoplasm Patients with U2AF1 Mutations
4350 - Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
4362 - CPX-351 for Blast-Phase Myeloproliferative Neoplasm (MPN-BP): Mayo Clinic Experience in 10 Consecutive Patients
4375 - Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
Tegegn, M.
Tegla, C. A.
Teh, B. W.
Teh, C. H.
Teh, T. C.
606 - A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia
1443 - Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
1443 - Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
Tehlirian, C.
Teicher, B. A.
Teichmann, L. L.
53 - Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols
622 - Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia – an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
742 - Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
3057 - Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)
622 - Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia – an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
742 - Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
3057 - Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)
Teierle, S. M.
Teipel, R.
1919 - A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell–Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
Teixeira, L. L.
Teixeira, M. M.
Teixeira, P. C.
Tejada Chaves, C. D.
Tejeira, N.
Tejero, J.
Tekle, C.
753 - Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis
3176 - Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment
4928 - Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status
3176 - Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Subgroup Analysis By Number of Prior Lines of Treatment
4928 - Isatuximab Plus Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma in Real-Life Context in France: IMAGE Subgroup Analysis Based on Prior Lines of Therapy and Refractory Status
Teklemichael, A.
915 - CD8+ TEMRA Clones Cause Platelet Lysis in Immune Thrombocytopenia
1134 - Characterisation of Platelet Sensitivity in Immune Thrombocytopenia Identifies Distinct Subgroups with Either Higher or Lower Platelet Sensitivity
2444 - Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Immune Thrombocytopaenia: a Multi-Centre Review
2447 - Cognitive Impairment in Patients with Immune Thrombocytopenia
2451 - Eltrombopag Causes Cell Cycle Arrest of T Cells through Iron Chelation and Could Modulate the Immune Response in ITP
1134 - Characterisation of Platelet Sensitivity in Immune Thrombocytopenia Identifies Distinct Subgroups with Either Higher or Lower Platelet Sensitivity
2444 - Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Immune Thrombocytopaenia: a Multi-Centre Review
2447 - Cognitive Impairment in Patients with Immune Thrombocytopenia
2451 - Eltrombopag Causes Cell Cycle Arrest of T Cells through Iron Chelation and Could Modulate the Immune Response in ITP
Telange, R.
Telatar, M.
Teleanu, M. V.
Telen, M. J.
Telenius, A.
71 - Spatial Tumor Microenvironment Characterization and Outcome of Relapsed/Refractory Classic Hodgkin Lymphoma
541 - Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling
844 - TRAF3 Loss-of-Function Reveals the Non-Canonical NF-Κb Pathway As a Therapeutic Target in Diffuse Large B-Cell Lymphoma
541 - Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling
844 - TRAF3 Loss-of-Function Reveals the Non-Canonical NF-Κb Pathway As a Therapeutic Target in Diffuse Large B-Cell Lymphoma
Telford, A.
Telonis, A. G.
Telzerow, E.
Tembhare, P. R.
469 - Circulating Clonal Plasma Cells at Diagnosis and Peripheral Blood Measurable Residual Disease Assessment Provide Powerful Prognostication Biomarkers in Newly-Diagnosed Multiple Myeloma Patients Treated without Autologous Transplant
1869 - Serum microRNA Signature Predicting Poor Therapeutic Response to Bortezomib-Based Therapy and Clinical Outcome in Newly Diagnosed Multiple Myeloma: A Result of miRNA Profiling By Deep Sequencing
2015 - Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India
3137 - Targeting Transcriptional Kinase of CDK7 Halts Proliferation of Multiple Myeloma Cells By Modulating the Function of Canonical NF-Kβ Pathway and Cell Cycle Regulatory Proteins
4016 - Identification of Phenotypic Subgroups of Acute Myeloid Leukemia, Defined By Differentiation According to Who 2022 Classification
4641 - Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy
1869 - Serum microRNA Signature Predicting Poor Therapeutic Response to Bortezomib-Based Therapy and Clinical Outcome in Newly Diagnosed Multiple Myeloma: A Result of miRNA Profiling By Deep Sequencing
2015 - Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India
3137 - Targeting Transcriptional Kinase of CDK7 Halts Proliferation of Multiple Myeloma Cells By Modulating the Function of Canonical NF-Kβ Pathway and Cell Cycle Regulatory Proteins
4016 - Identification of Phenotypic Subgroups of Acute Myeloid Leukemia, Defined By Differentiation According to Who 2022 Classification
4641 - Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy
Temple, W. C.
Ten Buren, E.
ten Cate, H.
Ten Hacken, E.
Tenbusch, M.
Tenenbaum, A.
100 - Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens
174 - Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin
1852 - Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma
174 - Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin
1852 - Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma
Teng, G.
1722 - Comparison of the Efficacy and Safety of Pegylated Interferon Alpha-2b and Common Interferon Alpha in Patients with Myeloproliferative Neoplasms
4373 - Mild Fibrosis (MF-1) Increases the Risk of Secondary Cancers in Patients with Myeloproliferative Neoplasms-Clinical Characteristics of 1060 Myeloproliferative Neoplasms Patients with Secondary Cancers
4373 - Mild Fibrosis (MF-1) Increases the Risk of Secondary Cancers in Patients with Myeloproliferative Neoplasms-Clinical Characteristics of 1060 Myeloproliferative Neoplasms Patients with Secondary Cancers
Teng, X.
Tenge, C. N.
4161 - Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
Tennant, D. A.
Tentori, C. A.
Teo, J.
Teodorescu, P.
Teoh, C. M.
Teoh, P. J.
Teoh, P. J.
Teperino, R.
Teque, F.
ter Haak, M.
Terakura, S.
Teramo, A.
Terao, C.
Terao, T.
756 - Anti-Sars-Cov-2 Antibody and T-Cell Responses Using Deep T-Cell Receptor Immunosequencing after Vaccination Among Healthy Individuals and Patients with Multiple Myeloma or Lymphoma
1427 - Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML
2977 - Prospective Study of the Usefulness of Liquid Biopsy in Patients with Unknown Fever Suspected of Malignant Lymphoma
4179 - Humoral Response to the Third-Dose COVID-19 Vaccination in Patients with Hematological Malignancy
1427 - Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML
2977 - Prospective Study of the Usefulness of Liquid Biopsy in Patients with Unknown Fever Suspected of Malignant Lymphoma
4179 - Humoral Response to the Third-Dose COVID-19 Vaccination in Patients with Hematological Malignancy
Terasaki, T.
Terauchi, T.
Terebelo, H. R.
Terekhova, M.
Terkawi, L.
Terlinden, A.
Termini, C.
Termuhlen, A. M.
Ternette, N.
Terol, M. J.
764 - Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
4210 - Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group
4448 - Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study
4210 - Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group
4448 - Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study
Terpitz, U.
Terpos, E.
474 - Prognostic Significance of Circulating Plasma Cells Detected By Next Generation Flow Cytometry in Light (AL) Chain Amyloidosis
647 - Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis
1180 - Persisting Endothelial Cell Activation and Hypercoagulability after Recovering from COVID-19: The Roadmap-Post COVID-19 Study
1859 - Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study
1861 - Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy
1863 - Prevalence of Monoclonal Gammopathy of Clinical Significance (MGCS) Among Patients with Monoclonal Gammopathies: Report from a Referral Center
1913 - Improved Survival of Patients with Primary Plasma Cell Leukemia with VRD or Daratumumab-Based Quadruplets: A Multicenter Study By the Greek Myeloma Study Group
1920 - A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
3167 - Genomic Landscape of IgM MGUS and Asymptomatic Waldenström Macroglobulinemia Patients
3181 - Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes
3221 - The Cancer-Related Circrna Cirs-7 (CDR1-AS) Is Differentially Expressed in CD138+ Cells of Patients with Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma
3234 - Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
3242 - MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
3243 - MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody
3256 - Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies
4299 - Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era
4558 - MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant
4569 - Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)
647 - Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis
1180 - Persisting Endothelial Cell Activation and Hypercoagulability after Recovering from COVID-19: The Roadmap-Post COVID-19 Study
1859 - Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study
1861 - Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy
1863 - Prevalence of Monoclonal Gammopathy of Clinical Significance (MGCS) Among Patients with Monoclonal Gammopathies: Report from a Referral Center
1913 - Improved Survival of Patients with Primary Plasma Cell Leukemia with VRD or Daratumumab-Based Quadruplets: A Multicenter Study By the Greek Myeloma Study Group
1920 - A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
3167 - Genomic Landscape of IgM MGUS and Asymptomatic Waldenström Macroglobulinemia Patients
3181 - Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes
3221 - The Cancer-Related Circrna Cirs-7 (CDR1-AS) Is Differentially Expressed in CD138+ Cells of Patients with Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma
3234 - Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
3242 - MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
3243 - MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody
3256 - Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies
4299 - Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era
4558 - MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant
4569 - Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)
Terpos, E.
1889 - Antibody Response to COVID-19 mRNA Vaccine in Patients with Multiple Myeloma and Waldenstrom’s Macroglobulinemia after Primary Immunization and Booster: Reactivity to the Sars-Cov-2 WT Virus, Delta and Omicron Variants
3236 - Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
3236 - Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
Terpstra, V.
68 - Special Anatomical Subtypes of Diffuse Large B-Cell Lymphoma Have Distinct Tumor Microenvironments
152 - Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen
1535 - Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival
152 - Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen
1535 - Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival
Terragna, C.
Terrazas, D.
3458 - Lentiviral Gene Therapy with Low Dose Conditioning for X-Linked SCID Results in Complete Immune Reconstitution and No Evidence of Clonal Expansion
3460 - Interim Results from an Ongoing Phase 1/2 Study of Lentiviral-mediated Ex-vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
4784 - Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial
3460 - Interim Results from an Ongoing Phase 1/2 Study of Lentiviral-mediated Ex-vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
4784 - Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial
Terré, C.
Terrell, D. R.
Terreros, E.
Terrier, B.
Terriou, L.
23 - Platelet Count Threshold Associated with Bleeding in Adult Patients with Immune Thrombocytopenia Treated with Antiplatelet Drugs. Results from the Carmen-France Registry
2449 - Multirefractory Primary Immune Thrombocytopenia in Adults: Prevalence and Burden. Results from the Carmen-France Registry
2449 - Multirefractory Primary Immune Thrombocytopenia in Adults: Prevalence and Burden. Results from the Carmen-France Registry
Terris, C.
Tersteeg, C.
Teruel, A. I.
118 - Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
1827 - Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
1827 - Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
Teruel Montoya, R.
Terui, K.
605 - Evaluation of High-Dose Cytarabine Induction Therapy and Flow Cytometric Measurable Residual Disease Monitoring for Children with De Novo Acute Myeloid Leukemia: A Report from the JPLSG-AML-12 Trial
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
Terzi Di Bergamo, L.
1785 - The CXCR4dim/CD5bright Proliferative Fraction Reappears in Relapsed CLL Under Ibrutinib, Enriched in BTK Mutations
1989 - PI3K and BTK Inhibition Induces the Upregulation of CD19 and Increases Sensitivity to CAR T Cells in a Model of Marginal Zone Lymphoma (MZL)
4158 - Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients
4422 - Clonal Evolution of Chronic Lymphocytic Leukemia with Bimodal CD49d Expression Reveals CD49d Plasticity
1989 - PI3K and BTK Inhibition Induces the Upregulation of CD19 and Increases Sensitivity to CAR T Cells in a Model of Marginal Zone Lymphoma (MZL)
4158 - Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients
4422 - Clonal Evolution of Chronic Lymphocytic Leukemia with Bimodal CD49d Expression Reveals CD49d Plasticity
Tesch, H.
Tesch, H.
Teschemaker, A.
Teschemaker, A.
Teshigawara, H.
Teshima, T.
321 - Novel Simple Prognostic Index (NJHSG-PI) Can Effectively Predict Prognosis in Patients with Newly Diagnosed DLBCL : A Real World Analysis across 14 Cancer Centers in Japan
324 - Incidentally Detected Complex Karyotypic Abnormalities in the Bone Marrow Provide a Clue to Diagnosing Intravascular Large B-Cell Lymphoma
439 - YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update
478 - Calcineurin Inhibitors Inhibit Tolerance Induction By Suppressing Terminal Differentiation of Donor Exhausted T Cells after Allogeneic SCT
608 - Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial
974 - Intercellular Mitochondrial Transfer Enhances Metabolic Fitness and Anti-Tumor Effects of CAR T Cells
1390 - Clinical Features of Complex Karyotype in Newly Diagnosed Acute Myeloid Leukemia
2054 - International Collaborative Study to Compare the Prognosis for Acute Leukemia Patients Transplanted with Intensified Myeloablative Regimens
2987 - Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma
4036 - Prognostic Impact of CEBPA bZIP Domain Mutation in Cytogenetically Normal Acute Myeloid Leukemia
4095 - Subclinical Minute FLT3-ITD Clone Can be Detected in Clinically FLT3-ITD-Negative Acute Myeloid Leukemia
4150 - Better Prognosis of Dominant-Negative Type of IKZF1 Deletion in BCR-ABL-positive Adult B-Cell Acute Lymphoblastic Leukemia
4396 - Booster Effect of a Third mRNA-Based COVID-19 Vaccine Dose in Patients with Myeloid Malignancies
324 - Incidentally Detected Complex Karyotypic Abnormalities in the Bone Marrow Provide a Clue to Diagnosing Intravascular Large B-Cell Lymphoma
439 - YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update
478 - Calcineurin Inhibitors Inhibit Tolerance Induction By Suppressing Terminal Differentiation of Donor Exhausted T Cells after Allogeneic SCT
608 - Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial
974 - Intercellular Mitochondrial Transfer Enhances Metabolic Fitness and Anti-Tumor Effects of CAR T Cells
1390 - Clinical Features of Complex Karyotype in Newly Diagnosed Acute Myeloid Leukemia
2054 - International Collaborative Study to Compare the Prognosis for Acute Leukemia Patients Transplanted with Intensified Myeloablative Regimens
2987 - Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma
4036 - Prognostic Impact of CEBPA bZIP Domain Mutation in Cytogenetically Normal Acute Myeloid Leukemia
4095 - Subclinical Minute FLT3-ITD Clone Can be Detected in Clinically FLT3-ITD-Negative Acute Myeloid Leukemia
4150 - Better Prognosis of Dominant-Negative Type of IKZF1 Deletion in BCR-ABL-positive Adult B-Cell Acute Lymphoblastic Leukemia
4396 - Booster Effect of a Third mRNA-Based COVID-19 Vaccine Dose in Patients with Myeloid Malignancies
Tessier, J. J.
Tesson, B.
Tessoulin, B.
553 - Late Failure of Aggressive B-Cell Lymphoma Following CAR T-Cell Therapy: A Lysa Study from the Descar-T Registry
845 - CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients
2680 - STP938, a Selective CTPS1 Inhibitor, Shows Single Agent Activity and Synergy with BCL2 Inhibition in Preclinical Models of Mantle Cell Lymphoma
3299 - Biological Differences between Axi-Cel and Tisa-Cel Products and Impacts on Outcomes in Lymphoma Patients
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4262 - A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
845 - CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients
2680 - STP938, a Selective CTPS1 Inhibitor, Shows Single Agent Activity and Synergy with BCL2 Inhibition in Preclinical Models of Mantle Cell Lymphoma
3299 - Biological Differences between Axi-Cel and Tisa-Cel Products and Impacts on Outcomes in Lymphoma Patients
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4262 - A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
Tettamanti, S.
1962 - Overexpression of CXCR4 Enhances the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia
1996 - Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT
4597 - Tuned IL3-Zetakine Coupled to a CD33 Costimulatory Receptor As a Dual CAR for Safer and Selective Targeting of Acute Myeloid Leukemia
4644 - Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response
1996 - Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT
4597 - Tuned IL3-Zetakine Coupled to a CD33 Costimulatory Receptor As a Dual CAR for Safer and Selective Targeting of Acute Myeloid Leukemia
4644 - Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response
Tettero, J. M.
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
838 - Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
4110 - Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
838 - Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
4110 - Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements
Tettey, Y.
Teuchter, W.
Teufel, E.
Teufel, E.
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
1860 - Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling
4473 - The T-Cell Metabolic Phenotype Is Dependent on Risk Status and Degree of PC Bone Marrow Infiltration in Multiple Myeloma
1860 - Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling
4473 - The T-Cell Metabolic Phenotype Is Dependent on Risk Status and Degree of PC Bone Marrow Infiltration in Multiple Myeloma
Tewari, S.
1418 - Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia
4052 - Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)
4052 - Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)
Texier, N.
1856 - Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study
1910 - What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort
3174 - Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study
1910 - What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort
3174 - Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study
Tey, S. K.
Teynor, M.
Tezotto, A. D. S.
Thabane, L.
Thadani-Mulero, M.
Thadi, A.
Thakar, H.
Thakar, M.
Thakkar, A.
268 - Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma
4919 - Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis
4919 - Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis
Thakkar, S. G.
Thakker, S.
Thakrar, N.
Thakur, I. R.
1418 - Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia
4052 - Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)
4052 - Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)
Thakurta, A.
Thalambedu, N.
3588 - Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy
3616 - Outcomes Among Hospitalized Multiple Myeloma Patients with Chronic Kidney Disease That Received Autologous Stem Cell Transplant: A Nationwide Analysis
4746 - Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
3616 - Outcomes Among Hospitalized Multiple Myeloma Patients with Chronic Kidney Disease That Received Autologous Stem Cell Transplant: A Nationwide Analysis
4746 - Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
Thaler, M.
Thall, P. F.
489 - High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas
875 - First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
3333 - A Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies
4738 - Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)
875 - First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
3333 - A Phase II Clinical Trial of “Off-the-Shelf” NK Cells with Allogeneic Stem Cell Transplantation to Decrease Disease Relapse in Patients with High-Risk Myeloid Malignancies
4738 - Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)
Tham, E.
Thamgrang, T.
Than, H.
2052 - Haploidentical Hematopoietic Cell Transplantation of Ex Vivo Tcrαβ-Depleted Grafts with CD45RA-Depleted Memory T Cell Add-Back Reduces Chronic Graft-Versus-Host Disease and Results in Favourable Gvhd-Relapse Free Survival: 5-Year Follow-up of 107 Patients Treated in a Multicenter Study in Singapore
3386 - Sequential Use of Flamsa, FLAG, CLAG or TEC-Based Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasia Patients: 15 Year Follow-up of the Multicenter Study in Singapore
4711 - Haploidentical Transplant Using Selective Ex-Vivo Tcrαβ Depleting and Memory T Cell Add-Back Results in More Favorable Gvhd-Free /Relapse Free Survival (GRFS) As Compared to Post-Transplant Cyclophosphamide for Adults with Hematological Malignancies - a Comparative Analysis of 170 Patients in a Multicenter Study in Singapore
3386 - Sequential Use of Flamsa, FLAG, CLAG or TEC-Based Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasia Patients: 15 Year Follow-up of the Multicenter Study in Singapore
4711 - Haploidentical Transplant Using Selective Ex-Vivo Tcrαβ Depleting and Memory T Cell Add-Back Results in More Favorable Gvhd-Free /Relapse Free Survival (GRFS) As Compared to Post-Transplant Cyclophosphamide for Adults with Hematological Malignancies - a Comparative Analysis of 170 Patients in a Multicenter Study in Singapore
Thanarajasingam, G.
Thanendrarajan, S.
106 - A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance
1909 - Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
3588 - Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy
4545 - Variability of Definition of High-Risk Multiple Myeloma in Phase III Clinical Trials
4746 - Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
1909 - Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
3588 - Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy
4545 - Variability of Definition of High-Risk Multiple Myeloma in Phase III Clinical Trials
4746 - Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
Thankachan, J.
213 - Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study
831 - Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
4043 - The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study
831 - Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
4043 - The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study
Thao, L. T.
930 - The Effect of Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Aspirin on Clinical Outcomes in the Healthy Elderly: A Sub-Study of the Aspirin in Reducing Events in the Elderly (ASPREE) Randomized Controlled Trial
3865 - The Growth Kinetics of Clonal Hematopoiesis Inform Risk of Blood Cancer Progression
3865 - The Growth Kinetics of Clonal Hematopoiesis Inform Risk of Blood Cancer Progression
Thapa, A.
822 - Novel Evidence That Intracellular Complement Network (complosome) Is Expressed in Hematopoietic Stem Cells (HSPCs) and Regulates Their Trafficking, Metabolism, and Proliferation in an Intracrine-Dependent Manner By Engaging Pattern Recognition Receptor Nlrp3 Inflammasome
1209 - Novel Evidence That Pineal Gland Hormone Melatonin Inhibits Migration of Hematopoietic Stem/Progenitor Cells (HSPCs) By Inhibiting Nlrp3 Inflammasome and Upregulating Heme Oxygenase-1 (HO-1) - Implications to Understand Better Diurnal Trafficking of HSPCs and Anti-Inflammatory Effects of Melatonin
1209 - Novel Evidence That Pineal Gland Hormone Melatonin Inhibits Migration of Hematopoietic Stem/Progenitor Cells (HSPCs) By Inhibiting Nlrp3 Inflammasome and Upregulating Heme Oxygenase-1 (HO-1) - Implications to Understand Better Diurnal Trafficking of HSPCs and Anti-Inflammatory Effects of Melatonin
Thapa, B.
Thapa, S.
Tharmaratnam, K.
Thatavarthi, U.
Thatavarty, A.
Thatcher, E.
Thaung Zaw, J. J.
1157 - Health-Related Quality of Life in Patients with Hemophilia A or B with Inhibitors on Concizumab Prophylaxis: Results from the Phase 3 explorer7 Study
2466 - Treatment Burden and Patient Preference in Patients with Hemophilia A or B with Inhibitors on Concizumab Prophylaxis: Results from the Phase 3 explorer7 Study
2466 - Treatment Burden and Patient Preference in Patients with Hemophilia A or B with Inhibitors on Concizumab Prophylaxis: Results from the Phase 3 explorer7 Study
Thavonekham, B.
Thavorn, K.
Thaxton, C. S.
2153 - Receptor Targeted Delivery of the p38γ Inhibitor PIK-75 By Organic-Core Templated Lipid Nanoparticles in Cutaneous T Cell Lymphoma
2656 - Synthetic Lipid Nanoparticles Actively Target Acute Myeloid Leukemia (AML) Cells and Induce Ferroptosis through Decreased Expression of Glutathione Peroxidase 4
2669 - Investigations of Redox Resistance in Aggressive Lymphomas with Cholesterol Modulating Lipid Nanoparticles
2656 - Synthetic Lipid Nanoparticles Actively Target Acute Myeloid Leukemia (AML) Cells and Induce Ferroptosis through Decreased Expression of Glutathione Peroxidase 4
2669 - Investigations of Redox Resistance in Aggressive Lymphomas with Cholesterol Modulating Lipid Nanoparticles
Thaxton, J. E.
Thein, K. Z.
3569 - Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy
4891 - Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Gastric and Gastro-Esophageal Junction (GEJ) Cancers Receiving Chemotherapy
4891 - Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Gastric and Gastro-Esophageal Junction (GEJ) Cancers Receiving Chemotherapy
Thein, S. L.
391 - AG-946 Normalizes Glycolysis and Improves Red Cell Indices in a Humanized Sickle Cell Mouse Model
393 - Pklr Variants Associated with Acute Pain in Sickle Cell Disease Influence ATP Concentrations in Red Blood Cells
1044 - The Pyruvate Kinase Activator Mitapivat Improves Red Blood Cell Deformability and Sickling Kinetics in Adult Patients with Sickle Cell Disease
1053 - Feasibility of Near-Infrared Spectroscopy for Monitoring Hemodynamic Changes in Patients with Sickle Cell Disease Treated with Mitapivat
2367 - Activating Pyruvate Kinase Improves Red Blood Cell Integrity By Reducing Band3 Tyrosine Phosphorylation
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
393 - Pklr Variants Associated with Acute Pain in Sickle Cell Disease Influence ATP Concentrations in Red Blood Cells
1044 - The Pyruvate Kinase Activator Mitapivat Improves Red Blood Cell Deformability and Sickling Kinetics in Adult Patients with Sickle Cell Disease
1053 - Feasibility of Near-Infrared Spectroscopy for Monitoring Hemodynamic Changes in Patients with Sickle Cell Disease Treated with Mitapivat
2367 - Activating Pyruvate Kinase Improves Red Blood Cell Integrity By Reducing Band3 Tyrosine Phosphorylation
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi
Theisen, O.
Theobald, M.
Theodorakakou, F.
474 - Prognostic Significance of Circulating Plasma Cells Detected By Next Generation Flow Cytometry in Light (AL) Chain Amyloidosis
647 - Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis
761 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
1861 - Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy
1863 - Prevalence of Monoclonal Gammopathy of Clinical Significance (MGCS) Among Patients with Monoclonal Gammopathies: Report from a Referral Center
1920 - A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
3167 - Genomic Landscape of IgM MGUS and Asymptomatic Waldenström Macroglobulinemia Patients
3181 - Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes
3221 - The Cancer-Related Circrna Cirs-7 (CDR1-AS) Is Differentially Expressed in CD138+ Cells of Patients with Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma
3234 - Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
3244 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
3256 - Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies
647 - Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis
761 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
1861 - Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy
1863 - Prevalence of Monoclonal Gammopathy of Clinical Significance (MGCS) Among Patients with Monoclonal Gammopathies: Report from a Referral Center
1920 - A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
3167 - Genomic Landscape of IgM MGUS and Asymptomatic Waldenström Macroglobulinemia Patients
3181 - Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes
3221 - The Cancer-Related Circrna Cirs-7 (CDR1-AS) Is Differentially Expressed in CD138+ Cells of Patients with Plasma Cell Disorders and Predicts Unfavorable Overall Survival in Multiple Myeloma
3234 - Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
3244 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
3256 - Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies
Theodorakopoulos, K.
Theodoropoulos, J.
Thepot, S.
460 - Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial
2765 - Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: The Phase 1b Cimon Trial
4377 - Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?
4407 - Prevalence of Osteoporosis in Myelodysplastic Syndrome Patients and Association with Cytopenias
4413 - Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351
2765 - Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: The Phase 1b Cimon Trial
4377 - Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?
4407 - Prevalence of Osteoporosis in Myelodysplastic Syndrome Patients and Association with Cytopenias
4413 - Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351
Theret, L.
Theurich, S.
1888 - Density of the Spleen in Low-Dose CT Scans Is Associated with High-Risk Disease Features and Shorter Survival in Newly Diagnosed Multiple Myeloma Patients
3343 - The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
4669 - Body Composition and Immunonutritional Status Impact Survival Outcomes after CD19 CAR T-Cell Therapy
3343 - The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
4669 - Body Composition and Immunonutritional Status Impact Survival Outcomes after CD19 CAR T-Cell Therapy
Thévenet, S.
Theves, F.
Thibaud, S.
249 - Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy
1874 - Extramedullary Relapse Post CAR-T
1914 - Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax
3203 - Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells
3315 - Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations
4525 - Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
1874 - Extramedullary Relapse Post CAR-T
1914 - Gain of chr1q Portends Poor Outcomes in Multiple Myeloma Patients Treated with Venetoclax
3203 - Timing and Nature of Infections in Multiple Myeloma Patients Treated with Anti-BCMA CAR-T Cells
3315 - Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations
4525 - Infections and Severe Hypogammaglobulinemia in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Thibault, P.
Thiebaut-Bertrand, A.
50 - In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival – Results from the Graall-2014 Trial
211 - Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
211 - Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
Thiebaut-Millot, R.
Thieblemont, C.
166 - Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study
233 - Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study
234 - Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial
259 - Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7
608 - Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial
767 - Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry
956 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”
1557 - Time to Complete Response within 24 Months As a Good Surrogate Marker of 8 Year-Progression Free Survival in Extranodal Marginal Zone Lymphoma
1596 - The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study
2277 - Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
2949 - Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
4270 - Clinical Research in Western Africa: Efficacy and Safety of a Phase II Study of R-CHOP in First-Line DLBCL in Senegal
4627 - A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)
4667 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
233 - Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study
234 - Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial
259 - Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7
608 - Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial
767 - Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry
956 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”
1557 - Time to Complete Response within 24 Months As a Good Surrogate Marker of 8 Year-Progression Free Survival in Extranodal Marginal Zone Lymphoma
1596 - The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study
2277 - Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
2949 - Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
4270 - Clinical Research in Western Africa: Efficacy and Safety of a Phase II Study of R-CHOP in First-Line DLBCL in Senegal
4627 - A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)
4667 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Thieblemont, C.
544 - Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial
2948 - Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study
3110 - Metabolic Reprogramming of Bone Marrow Stromal Cells in Chronic Lymphocytic Leukemia
3580 - Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)
4251 - Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
4278 - Clinical Research in Africa: Collaborative Project between Senegal and France to Improve the Diagnosis and Therapeutic Management of Adult Lymphoma Patients
2948 - Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study
3110 - Metabolic Reprogramming of Bone Marrow Stromal Cells in Chronic Lymphocytic Leukemia
3580 - Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)
4251 - Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
4278 - Clinical Research in Africa: Collaborative Project between Senegal and France to Improve the Diagnosis and Therapeutic Management of Adult Lymphoma Patients
Thiede, C.
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
564 - UBTF tandem Duplications Account for a Third of Advanced Pediatric MDS without Genetic Predisposition to Myeloid Neoplasia
1500 - Proteomic Characterization of Acute Myeloid Leukemia
1745 - Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
2786 - Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
2799 - Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
564 - UBTF tandem Duplications Account for a Third of Advanced Pediatric MDS without Genetic Predisposition to Myeloid Neoplasia
1500 - Proteomic Characterization of Acute Myeloid Leukemia
1745 - Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
2786 - Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
2799 - Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction
Thiel, K.
Thiel-Klare, K.
Thiele Orberg, E.
3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients
4590 - IFN-Gamma Is Crucial for the Counterbalance of T Cell-Mediated Injury to the Intestinal Stem Cell Compartment By Regulatory T Cells in Mice and Humans
4590 - IFN-Gamma Is Crucial for the Counterbalance of T Cell-Mediated Injury to the Intestinal Stem Cell Compartment By Regulatory T Cells in Mice and Humans
Thiele-Orberg, E.
Thies, M.
Thirlway, J.
Thirman, M. J.
63 - The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study
219 - Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
376 - Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
602 - ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine
849 - Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers
4055 - Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A
219 - Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
376 - Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience
602 - ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine
849 - Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers
4055 - Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A
Thiruganasambandamoorthy, V.
Thirunavukarasu, D.
Thol, F. R.
340 - TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis
832 - Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia
1437 - Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia
1466 - Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)
2704 - Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients
2782 - Prognostic Impact of Clonal Hierarchy of Myelodysplasia-Related Gene Mutations in AML Patients
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
4414 - Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features
832 - Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia
1437 - Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia
1466 - Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)
2704 - Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients
2782 - Prognostic Impact of Clonal Hierarchy of Myelodysplasia-Related Gene Mutations in AML Patients
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
4414 - Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features
Thölken, M.
Tholouli, E.
871 - Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation – a Registry Study on Behalf of the EBMT Acute Leukemia Working Party
4634 - First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
4634 - First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
Thomä, N.
Thomaides-Brears, H.
Thomas, A.
Thomas, A.
Thomas, B. E.
948 - A Single Cell Atlas and Interactive Web-Resource of Pediatric Cancers and Healthy Bone Marrow
1296 - Single-Cell Profiling of Acute Myeloid Leukemia Identified ARMH1, a Novel Protein Associated with Proliferation, Migration, and Drug Resistance
1475 - Connecting Genetic Heterogeneity with Single-Cell Transcriptome Dysregulations in Pediatric Acute Myeloid Leukemia
1296 - Single-Cell Profiling of Acute Myeloid Leukemia Identified ARMH1, a Novel Protein Associated with Proliferation, Migration, and Drug Resistance
1475 - Connecting Genetic Heterogeneity with Single-Cell Transcriptome Dysregulations in Pediatric Acute Myeloid Leukemia
Thomas, C. J.
931 - IRAK1 Contributes to IRAK4 Inhibitor Resistance Via Non-Canonical Signaling Mechanisms in MDS/AML
952 - Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease
2647 - Inhibition of Both IRAK1 and IRAK4 Is Required for Complete Suppression of NF-Kb Signaling across Multiple Receptor-Mediated Pathways in MDS and AML
2939 - Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy
952 - Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease
2647 - Inhibition of Both IRAK1 and IRAK4 Is Required for Complete Suppression of NF-Kb Signaling across Multiple Receptor-Mediated Pathways in MDS and AML
2939 - Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy
Thomas, D.
928 - Targeting IDH1-Mutated Pre-Leukemic Hematopoietic Stem Cells in Myeloid Disease, Including CCUS and AML
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4383 - Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4383 - Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
Thomas, D. A.
Thomas, G. E.
1289 - Intracellular IL-23 Receptor (IL-23R) Is Necessary for AML Viability and Regulates Mitotic Spindle and Centrosome Formation
3925 - Inhibiting the Mitochondrial RNA Degradosome Complex SUV3 and Pnpase Increases dsRNA in the Cytoplasm, Triggers a Viral Mimicry Response and Kills AML Cells and Progenitors
3925 - Inhibiting the Mitochondrial RNA Degradosome Complex SUV3 and Pnpase Increases dsRNA in the Cytoplasm, Triggers a Viral Mimicry Response and Kills AML Cells and Progenitors
Thomas, I.
220 - A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results
1463 - Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study
2799 - Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction
1463 - Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study
2799 - Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction
Thomas, III, M. E.
Thomas, M.
Thomas, N.
726 - Exploring Splicing Factor Aberrations As a Therapeutic Target in Mature B-Cell Malignancies
841 - Mutations of the RNA Binding Protein hnRNP U Modulate MYC Expression in MYC-Driven Lymphomas
4160 - Genome-Wide Methylation and Haplotype-Resolved Aberrant Somatic Hypermutation Patterns in B-Cell Lymphomas
841 - Mutations of the RNA Binding Protein hnRNP U Modulate MYC Expression in MYC-Driven Lymphomas
4160 - Genome-Wide Methylation and Haplotype-Resolved Aberrant Somatic Hypermutation Patterns in B-Cell Lymphomas
Thomas, N.
Thomas, P. G.
Thomas, R.
Thomas, S. J.
Thomas, S.
2017 - Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells
2774 - Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
2774 - Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Thomas, S. K.
115 - Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant
1924 - Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
1929 - Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis
3169 - Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment
4751 - Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience
1924 - Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
1929 - Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis
3169 - Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment
4751 - Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience
Thomas, T. S.
1865 - The Association between Body Mass Index Trajectory and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
1899 - The Association of Agent Orange Exposure Duration with Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma Progression: A Population-Based Study
3489 - Racial Difference in Dynamic Markers for Progression of MGUS Using Machine Learning Approaches
4503 - Association between SLGT2 Inhibitor Use and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
1899 - The Association of Agent Orange Exposure Duration with Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma Progression: A Population-Based Study
3489 - Racial Difference in Dynamic Markers for Progression of MGUS Using Machine Learning Approaches
4503 - Association between SLGT2 Inhibitor Use and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
Thomas, T.
Thomas, T.
Thomas, X.
62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
303 - Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group
2804 - LSC17 Score Is Complementary with Minimal Residual Disease to Stratify NPM1-Mutated Acute Myeloid Leukemia: An ALFA Study
303 - Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group
2804 - LSC17 Score Is Complementary with Minimal Residual Disease to Stratify NPM1-Mutated Acute Myeloid Leukemia: An ALFA Study
Thomas-Tikhonenko, A.
Thomas-Toth, A.
Thomassen, M.
Thomasson, R.
Thompson, A. A.
11 - Lovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study
2348 - Long Term Outcomes of 63 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials
2378 - Return Visit Rates after an Emergency Department Treat-and-Release Visit for Children with Sickle Cell Pain Episodes
3665 - Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia
4877 - Optimizing Shared Decision Making about Hydroxyurea in Young Children with Sickle Cell Anemia
- Session Introduction
- The Role of a Nationwide SCD Data Hub and Learning Community
- Moderated Q&A
- Conclusion
- Moderated Panel Q&A
- ASH RC Data Hub and Learning Community Programs
2348 - Long Term Outcomes of 63 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials
2378 - Return Visit Rates after an Emergency Department Treat-and-Release Visit for Children with Sickle Cell Pain Episodes
3665 - Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia
4877 - Optimizing Shared Decision Making about Hydroxyurea in Young Children with Sickle Cell Anemia
- Session Introduction
- The Role of a Nationwide SCD Data Hub and Learning Community
- Moderated Q&A
- Conclusion
- Moderated Panel Q&A
- ASH RC Data Hub and Learning Community Programs
Thompson, C. A.
798 - Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era
2949 - Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
4216 - Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome
- Screening for Radiation and Chemotherapy Late Effects (except cardiac)
2949 - Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
4216 - Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome
- Screening for Radiation and Chemotherapy Late Effects (except cardiac)
Thompson, E.
Thompson, E.
Thompson, E.
361 - KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation
869 - Differences in Single Cells between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance Are Driven By Different Factors
2779 - Molecular, Epigenetic, and Immune Landscape of TP53-mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
3166 - Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
3314 - KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation
4017 - Impact of Allelic State on Overall Survival in TP53-mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
869 - Differences in Single Cells between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance Are Driven By Different Factors
2779 - Molecular, Epigenetic, and Immune Landscape of TP53-mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
3166 - Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
3314 - KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation
4017 - Impact of Allelic State on Overall Survival in TP53-mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
Thompson, J. E.
58 - Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes in Intermediate Risk Cytogenetic Acute Myeloid Leukemia
128 - Impact of Therapy on the Anamnestic Response to Seasonal Influenza Vaccination in Patients with Myeloid Malignancies
1691 - Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study
4061 - MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis
128 - Impact of Therapy on the Anamnestic Response to Seasonal Influenza Vaccination in Patients with Myeloid Malignancies
1691 - Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study
4061 - MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis
Thompson, M. C.
750 - Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
1797 - Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
4438 - Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton’s Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation
1797 - Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
4438 - Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton’s Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation
Thompson, M. A.
Thompson, M. A.
Thompson, M. A.
Thompson, P. A.
95 - Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data
96 - Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year
206 - Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader
208 - Pharmacological Profiling of Cells from Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Pirtobrutinib
216 - Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial
347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
831 - Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
1411 - A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
1801 - High Cell Death Rates at Start of Ibrutinib Therapy Predict for Deeper Remissions in Patients with Chronic Lymphocytic Leukemia (CLL)
1807 - Tolerability of Acalabrutinib after Prior Ibrutinib Treatment in Patients with CLL: Experience of a Tertiary Cancer Care Center
2956 - Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma
4043 - The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study
4224 - Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia
4435 - Early Treatment with Ofatumumab in Patients with High-Risk CLL
4914 - Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies
96 - Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year
206 - Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader
208 - Pharmacological Profiling of Cells from Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Pirtobrutinib
216 - Adct-602, a CD22 Targeting Antibody Drug Conjugate Bound to PBD Toxin in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase 1 Trial
347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
831 - Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
1411 - A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
1801 - High Cell Death Rates at Start of Ibrutinib Therapy Predict for Deeper Remissions in Patients with Chronic Lymphocytic Leukemia (CLL)
1807 - Tolerability of Acalabrutinib after Prior Ibrutinib Treatment in Patients with CLL: Experience of a Tertiary Cancer Care Center
2956 - Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma
4043 - The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study
4224 - Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia
4435 - Early Treatment with Ofatumumab in Patients with High-Risk CLL
4914 - Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies
Thompson, S.
Thompson, T.
Thompson, Z.
Thompson-Peach, C. A.
Thoms, J. A.
90 - Genome-Wide CRISPR-Cas9 Screening Identifies a Synergy between Hypomethylating Agents and Sumoylation Blockade in Myelodysplastic Syndromes and Acute Myeloid Leukemia
1211 - Comparative Analysis of Genome-Scale Gene Regulatory Networks in Human Hematopoietic Stem and Myeloid Progenitor Fractions
3080 - In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial
4381 - Clinical Response to Azacytidine (AZA) Is Associated with Increased Contribution from Mutated Blood Progenitors: Insights from Single Cell Genotyping of Matched Stem/Progenitor and Mature Blood Cells from MDS/CMML Patients Pre- and Post-AZA Treatment
1211 - Comparative Analysis of Genome-Scale Gene Regulatory Networks in Human Hematopoietic Stem and Myeloid Progenitor Fractions
3080 - In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial
4381 - Clinical Response to Azacytidine (AZA) Is Associated with Increased Contribution from Mutated Blood Progenitors: Insights from Single Cell Genotyping of Matched Stem/Progenitor and Mature Blood Cells from MDS/CMML Patients Pre- and Post-AZA Treatment
Thomsen, C.
Thomsen, T.
Thomson, H.
Thomson, K.
Thong, Y. L.
Thongjuea, S.
453 - Cross-Talk between Hematopoietic Cells and Fibroblast Subsets Drives Inflammation and Remodelling of the Bone Marrow Microenvironment in Myeloproliferative Neoplasms
4382 - Single-Cell Transcriptome Analysis Reveals Pathways That Drive Dyserythropoiesis in Myelodysplastic Syndromes, Which Are Targeted By Luspatercept
4382 - Single-Cell Transcriptome Analysis Reveals Pathways That Drive Dyserythropoiesis in Myelodysplastic Syndromes, Which Are Targeted By Luspatercept
Thongon, N.
Thongthip, S.
Thonier, V.
Thorat, J.
1397 - Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (pRISM) of the Hematology Cancer Consortium (HCC)
1407 - Real-World Outcomes for Acute Promyelocytic Leukemia: Need to Address Induction Mortality
2015 - Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India
2976 - Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemiafrom a Low-Middle Income Country: An Experience from Hematology Cancer Consortium
3628 - Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
4641 - Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy
1407 - Real-World Outcomes for Acute Promyelocytic Leukemia: Need to Address Induction Mortality
2015 - Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India
2976 - Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemiafrom a Low-Middle Income Country: An Experience from Hematology Cancer Consortium
3628 - Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
4641 - Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy
Thordardottir, A. R.
103 - Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
Thórdardottir, Á. R.
107 - Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort
3188 - Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
4455 - Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study
3188 - Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
4455 - Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study
Thordardottir, T.
Thorley, E.
915 - CD8+ TEMRA Clones Cause Platelet Lysis in Immune Thrombocytopenia
1134 - Characterisation of Platelet Sensitivity in Immune Thrombocytopenia Identifies Distinct Subgroups with Either Higher or Lower Platelet Sensitivity
2444 - Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Immune Thrombocytopaenia: a Multi-Centre Review
2451 - Eltrombopag Causes Cell Cycle Arrest of T Cells through Iron Chelation and Could Modulate the Immune Response in ITP
1134 - Characterisation of Platelet Sensitivity in Immune Thrombocytopenia Identifies Distinct Subgroups with Either Higher or Lower Platelet Sensitivity
2444 - Safety and Efficacy of SARS-CoV-2 Vaccination in Patients with Immune Thrombocytopaenia: a Multi-Centre Review
2451 - Eltrombopag Causes Cell Cycle Arrest of T Cells through Iron Chelation and Could Modulate the Immune Response in ITP
Thornburg, C. D.
28 - U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics
30 - Clinical and Treatment Characteristics of Infants and Toddlers Less Than Two Years of Age with Hemophilia: A Report from the Community Counts Registry
30 - Clinical and Treatment Characteristics of Infants and Toddlers Less Than Two Years of Age with Hemophilia: A Report from the Community Counts Registry
Thornton, A.
Thornton, J. A.
Thornton, P.
345 - Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment – Outcome Results from the CLL13/GAIA Trial
346 - High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
346 - High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
Thornton Snider, J.
Thorsgaard, M.
Thorsson, H.
Thorsteinsdottir, I.
103 - Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
Thorsteinsdottir, I.
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
Thorsteinsdóttir, I.
3188 - Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
4455 - Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study
4455 - Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study
Thorsteinsdottir, S.
103 - Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
- The Consultant’s Guide to Smoldering Multiple Myeloma
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
- The Consultant’s Guide to Smoldering Multiple Myeloma
Thorsteinsdóttir, S.
107 - Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort
3188 - Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
4455 - Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study
4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
3188 - Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
4455 - Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study
4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study
Thorsteinsson, A. L.
Thorwaldson, J.
Thota, P.
Thota, S.
385 - Risk Factors Beyond Chemo-Radiotherapy Exposure for Therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid Leukemia (tAML) Development in Breast Cancer Survivors: A 15-Year SEER-Medicare Analysis
2567 - Intense Immunosuppressive Therapy (anti-thymocyte globulin, alemtuzumab) As Salvage Therapy in Refractory T-Cell Large Granular Lymphocytic Leukemia and Pure Red Cell Aplasia
4414 - Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features
2567 - Intense Immunosuppressive Therapy (anti-thymocyte globulin, alemtuzumab) As Salvage Therapy in Refractory T-Cell Large Granular Lymphocytic Leukemia and Pure Red Cell Aplasia
4414 - Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features
Thotamgari, S. R.
Thouvenin, S.
Thrasher, A. J.
782 - Biochemical Engraftment and Clinical Outcomes Following Ex-Vivo Autologous Stem Cell Gene Therapy for Mucopolysaccharidosis Type IIIA
2348 - Long Term Outcomes of 63 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials
3458 - Lentiviral Gene Therapy with Low Dose Conditioning for X-Linked SCID Results in Complete Immune Reconstitution and No Evidence of Clonal Expansion
3460 - Interim Results from an Ongoing Phase 1/2 Study of Lentiviral-mediated Ex-vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
3665 - Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia
4584 - Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties
4774 - Long-Term Outcome of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) Using an Enhancer-Deleted Self-Inactivating Gammaretroviral Vector
4775 - Lentiviral-mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials
2348 - Long Term Outcomes of 63 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials
3458 - Lentiviral Gene Therapy with Low Dose Conditioning for X-Linked SCID Results in Complete Immune Reconstitution and No Evidence of Clonal Expansion
3460 - Interim Results from an Ongoing Phase 1/2 Study of Lentiviral-mediated Ex-vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
3665 - Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia
4584 - Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties
4774 - Long-Term Outcome of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) Using an Enhancer-Deleted Self-Inactivating Gammaretroviral Vector
4775 - Lentiviral-mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials
Thuret, I.
2348 - Long Term Outcomes of 63 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials
3665 - Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia
3665 - Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia
Thurin, M.
Thuring, J. W.
Thurner, L.
1309 - Hyper N-Glycosylated SEL1L3 As B-Cell Receptor Autoantigen of Primary Vitreoretinal Lymphoma
LBA-3 - Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
LBA-3 - Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)
Tiab, M.
3245 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
4553 - Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
4559 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
4553 - Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
4559 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
Tian, A.
Tian, L.
Tian, L.
1949 - ER Stress Sensor PERK Regulates T-Cell Allogeneic and Anti-Tumor Responses Distinctly
1952 - Retinoic Acid Regulates Donor Myeloid Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation in Mice
1957 - S1P/S1PR1 Signaling Differentially Regulates Allogeneic Response of CD4 and CD8 T Cells through Modulating Mitochondrial Content and Metabolism
1952 - Retinoic Acid Regulates Donor Myeloid Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation in Mice
1957 - S1P/S1PR1 Signaling Differentially Regulates Allogeneic Response of CD4 and CD8 T Cells through Modulating Mitochondrial Content and Metabolism
Tian, M.
Tian, S.
Tian, W.
1322 - Novel Sirpα-Fc Fusion Protein IMM01 Exhibits Dual Anti-Tumor Activities By Targeting CD47/Sirpα Signal Pathway
1585 - A First-in-Human Phase I Dose Escalation Study of IMM01, Sirpα Fc Protein in Patients with Relapsed or Refractory Lymphoma
4200 - Preliminary Safety and Efficacy Evaluation of IMM0306, a CD47 and CD20 Bispecific Monoclonal Antibody-Trap (mAb-Trap), from an Ongoing Phase I Dose-Escalation Study in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL)
1585 - A First-in-Human Phase I Dose Escalation Study of IMM01, Sirpα Fc Protein in Patients with Relapsed or Refractory Lymphoma
4200 - Preliminary Safety and Efficacy Evaluation of IMM0306, a CD47 and CD20 Bispecific Monoclonal Antibody-Trap (mAb-Trap), from an Ongoing Phase I Dose-Escalation Study in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL)
Tian, X.
Tian, X.
Tian, Y.
3398 - Association between Haploidentical Hematopoietic Stem Cell Transplantation Combined with an Umbilical Cord Blood Unit and Graft-Versus-Host Disease in Pediatric Patients with Acquired Severe Aplastic Anemia
3933 - Anagrelide Represents a Potential Therapeutic Therapy for Acute Myeloid Leukemia Cells Based on Phosphodiesterase 3A Expression
4691 - Improved Grfs Observed in a Multicenter Prospective Study of Tcrαβ- and CD45RA-Depleted Haploidentical Transplant in Children with Acute Leukemia
4723 - The Association of pDC Dose in Graft with CMV and EBV Infection after Allo-HSCT in Pediatric Patients: A Single-Center Experience
3933 - Anagrelide Represents a Potential Therapeutic Therapy for Acute Myeloid Leukemia Cells Based on Phosphodiesterase 3A Expression
4691 - Improved Grfs Observed in a Multicenter Prospective Study of Tcrαβ- and CD45RA-Depleted Haploidentical Transplant in Children with Acute Leukemia
4723 - The Association of pDC Dose in Graft with CMV and EBV Infection after Allo-HSCT in Pediatric Patients: A Single-Center Experience
Tian, Z.
Tian, Z.
1290 - Investigation of Impact Induced By AML1-ETO on Self-Renewal and Differentiation of Hematopoietic Stem and Progenitor Cells in Pre-Leukemic Stage
1419 - Construction of Dual- and Enhanced Dual-Antibodies Targeting CD19 in the Treatment of B-ALL and Investigation of the Relevant Mechanisms
1980 - Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells
3295 - The Investigation of Antitumor Effect of Humanized Bispecific BCMA/CD38 CAR-T Cells on Multiple Myeloma
1419 - Construction of Dual- and Enhanced Dual-Antibodies Targeting CD19 in the Treatment of B-ALL and Investigation of the Relevant Mechanisms
1980 - Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells
3295 - The Investigation of Antitumor Effect of Humanized Bispecific BCMA/CD38 CAR-T Cells on Multiple Myeloma
Tian, Z.
Tian, Z.
Tiberio, G.
Tibshirani, R.
Tibullo, D.
Ticchioni, M.
Tichy, D.
Tick, L. W.
950 - Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
1645 - First-Line Treatment and Outcome of T-Cell Prolymphocytic Leukemia in the Netherlands; A Nationwide Population-Based Study
1800 - Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/Sll; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial
1645 - First-Line Treatment and Outcome of T-Cell Prolymphocytic Leukemia in the Netherlands; A Nationwide Population-Based Study
1800 - Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/Sll; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial
Tickle, K.
Ticozzi, C.
Tiedemann, R. E.
Tiefgraber, M.
Tien, H. F.
56 - Prognostic Relevance of Adult Acute Myeloid Leukemia Patients According to the 2022 European Leukemianet Risk Stratification
458 - A Three Gene Leukemic Stem Cell Signature Score Is Robustly Prognostic in Chronic Myelomonocytic Leukemia
1106 - Conditional Knock-out of Phf6 Decreases CD44 Expression on Naïve CD4+ T Cells and Skews the Differentiation Toward Regulatory T Cells in Mice
3082 - Effect of Mutation Allele Frequency on the Risk Stratification of Myelodysplastic Syndrome Patients
458 - A Three Gene Leukemic Stem Cell Signature Score Is Robustly Prognostic in Chronic Myelomonocytic Leukemia
1106 - Conditional Knock-out of Phf6 Decreases CD44 Expression on Naïve CD4+ T Cells and Skews the Differentiation Toward Regulatory T Cells in Mice
3082 - Effect of Mutation Allele Frequency on the Risk Stratification of Myelodysplastic Syndrome Patients
Tieng, J.
Tierens, A.
2857 - Gene Expression Analysis Reveals Downregulation of Complement Receptor 1 in Cold Agglutinin Disease
4109 - The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy
4324 - Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy
4737 - Immunophenotypic Switch in Leukemic Clone Is Very Common at the Time of Post-Transplant Relapse of Acute Myeloid Leukemia While Immunophenotypic Profile at Diagnosis Correlates with Adverse Outcomes after Post-Transplant Relapse
4109 - The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy
4324 - Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy
4737 - Immunophenotypic Switch in Leukemic Clone Is Very Common at the Time of Post-Transplant Relapse of Acute Myeloid Leukemia While Immunophenotypic Profile at Diagnosis Correlates with Adverse Outcomes after Post-Transplant Relapse
Tiessen, J.
Tijani, L.
Tijmensen, J.
2065 - Effects of HLA Mismatches on Cytokine Release Syndrome and Associated Non-Relapse Mortality in Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide
3446 - Prophylactic Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Is Associated with Low Relapse Risk and Excellent Survival in Patients below 65 Years with Acute Myeloid Leukemia and High-Risk Myelodysplasia
3446 - Prophylactic Donor Lymphocyte Infusion in Patients after Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Is Associated with Low Relapse Risk and Excellent Survival in Patients below 65 Years with Acute Myeloid Leukemia and High-Risk Myelodysplasia
Tikhonova, A. N.
Tilahun, A.
Tiley, C.
Tilgner, M.
Till, B. G.
77 - Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411
2913 - Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume
3316 - Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
3321 - Long-term Follow-up of CD20-directed Chimeric Antigen Receptor Adoptive T-cell Therapy
4654 - CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study
2913 - Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume
3316 - Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
3321 - Long-term Follow-up of CD20-directed Chimeric Antigen Receptor Adoptive T-cell Therapy
4654 - CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study
Tillman, B. F.
Tillman, H.
Tilly, H.
542 - Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study
544 - Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial
1596 - The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study
2878 - Sub-Cutaneous Administration of Rituximab Triggers a Pro-Phagocytic Phenotype of Monocytic Compartment in Low-Tumor Burden Follicular Lymphoma Patients Included in the Flirt Clinical Trial, a Lysa Study
2883 - Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study
2948 - Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study
2958 - Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study
4262 - A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
544 - Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial
1596 - The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study
2878 - Sub-Cutaneous Administration of Rituximab Triggers a Pro-Phagocytic Phenotype of Monocytic Compartment in Low-Tumor Burden Follicular Lymphoma Patients Included in the Flirt Clinical Trial, a Lysa Study
2883 - Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study
2948 - Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study
2958 - Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study
4262 - A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis
Tilmont, R.
101 - Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)
864 - Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma
4476 - CRBN Structural Changes, Copy Number Changes and COP9 Signalosome Subunits Gene Expression Mediate Sensitivity to New Celmod Compound CC-92480 in Multiple Myeloma Patients
864 - Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma
4476 - CRBN Structural Changes, Copy Number Changes and COP9 Signalosome Subunits Gene Expression Mediate Sensitivity to New Celmod Compound CC-92480 in Multiple Myeloma Patients
Timilsina, S.
Timmer, C.
Timmer, M.
Timmerman, J.
316 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti–PD-1 Treatment
2910 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
4667 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
2910 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
4667 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Timmers, C.
Timmons, M.
Timofeeva, M. A.
Timofeeva, N.
Timonian, M.
354 - Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
Tinajero, J.
Tinchon, C.
561 - Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine – a Prospective Cohort Study By the AGMT
4572 - Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)
4572 - Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)
Ting, D. T.
Ting, E. B.
Ting, S. B.
711 - High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial
1252 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia – the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials
1456 - High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
1252 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia – the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials
1456 - High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
Tini, V.
Tinmouth, A.
Tinsley-Vance, S. M.
457 - Efficacy and Safety of Ruxolitinib for Treatment of Symptomatic Chronic Myelomonocytic Leukemia (CMML): Results of a Multicenter Phase II Clinical Trial
463 - A Product of “Clash of Titans” or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome
465 - Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes
3073 - Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes
3099 - Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal
3631 - Discordance between Patient Goals and Treatment in Older AML Patients
4410 - Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes
463 - A Product of “Clash of Titans” or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome
465 - Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes
3073 - Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes
3099 - Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal
3631 - Discordance between Patient Goals and Treatment in Older AML Patients
4410 - Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes
Tinterri, B.
Tiong, I. S.
606 - A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia
711 - High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial
840 - Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy
1226 - Allogeneic Hematopoietic Cell Transplantation (HCT) and Impact on Clonal Haematopoiesis and Post-HCT Therapy-Related Myeloid Neoplasm in Heavily Treated and Poor Risk Patients with Plasma Cell Myeloma
1447 - ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
1779 - Favorable Outcomes of DDX41-Mutated MDS and Low Blast Count AML Treated with Azacitidine with or without Lenalidomide (ALLG MDS4 Trial)
2784 - Intensified Induction Chemotherapy Results in More Rapid Early NPM1 Mutant (mut) Measurable Residual Disease (MRD) Clearance but Similar Disease Outcomes
3901 - Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy
4816 - Utility of High-Throughput Sequencing of Immunoglobulin Genes for MRD in Lymphoid Malignancy in the Context of Current Immunotherapeutics
711 - High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial
840 - Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy
1226 - Allogeneic Hematopoietic Cell Transplantation (HCT) and Impact on Clonal Haematopoiesis and Post-HCT Therapy-Related Myeloid Neoplasm in Heavily Treated and Poor Risk Patients with Plasma Cell Myeloma
1447 - ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
1779 - Favorable Outcomes of DDX41-Mutated MDS and Low Blast Count AML Treated with Azacitidine with or without Lenalidomide (ALLG MDS4 Trial)
2784 - Intensified Induction Chemotherapy Results in More Rapid Early NPM1 Mutant (mut) Measurable Residual Disease (MRD) Clearance but Similar Disease Outcomes
3901 - Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy
4816 - Utility of High-Throughput Sequencing of Immunoglobulin Genes for MRD in Lymphoid Malignancy in the Context of Current Immunotherapeutics
Tirado, N.
Tiribelli, M.
1700 - Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A “Campus CML” Study
1706 - Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A “Campus CML” Study
4355 - Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)
1706 - Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A “Campus CML” Study
4355 - Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)
Tirier, S. M.
Tischer, J.
2095 - Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT
2129 - Presence of Measurable Residual Disease in NPM1 Positive AML in Remission Pre-Transplant Does Not Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation
3447 - A Second Haploidentical Stem Cell Transplantation (HAPLO-SCT2) after Relapse from First Haplo-SCT Is Feasible and Produces Results That Are Comparable to Data Reported after Second SCT in an HLA-Matched Setting - a Study on Behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
3450 - Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation
4690 - Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML – Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI
4732 - Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
4761 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT
2129 - Presence of Measurable Residual Disease in NPM1 Positive AML in Remission Pre-Transplant Does Not Impact on Survival after Allogeneic Hematopoietic Stem Cell Transplantation
3447 - A Second Haploidentical Stem Cell Transplantation (HAPLO-SCT2) after Relapse from First Haplo-SCT Is Feasible and Produces Results That Are Comparable to Data Reported after Second SCT in an HLA-Matched Setting - a Study on Behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
3450 - Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation
4690 - Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML – Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI
4732 - Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
4761 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT
Tisdale, J.
3465 - Increased Potency and Uniformity of Fetal Hemoglobin Induction from Base Editing Compared to Cas9 Nuclease
3695 - A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Mgta-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia
3695 - A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Mgta-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia
Tisdale, J. F.
Tishena, A.
Tisi, M. C.
Tisserand, A.
Tissing, W. J.
215 - Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders
2730 - Variable Immune Response Following BNT162b2 mRNA COVID-19 Vaccination in Pediatric Patients with Hematological Malignancies Under Treatment
2730 - Variable Immune Response Following BNT162b2 mRNA COVID-19 Vaccination in Pediatric Patients with Hematological Malignancies Under Treatment
Tissing, W. J.
Tissino, E.
1785 - The CXCR4dim/CD5bright Proliferative Fraction Reappears in Relapsed CLL Under Ibrutinib, Enriched in BTK Mutations
1789 - An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients in Novel Categories with Different Risk of Early Treatment
4422 - Clonal Evolution of Chronic Lymphocytic Leukemia with Bimodal CD49d Expression Reveals CD49d Plasticity
1789 - An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients in Novel Categories with Different Risk of Early Treatment
4422 - Clonal Evolution of Chronic Lymphocytic Leukemia with Bimodal CD49d Expression Reveals CD49d Plasticity
Tittley, S.
Tiwari, A. D.
Tiwari, G.
Tiziani, S.
Tjon, J. M.
196 - High-Dimensional Mass Cytometric Analysis of the Bone Marrow Compartment Identifies a Disease-Specific Immune Cell Network in Aplastic Anemia
2065 - Effects of HLA Mismatches on Cytokine Release Syndrome and Associated Non-Relapse Mortality in Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide
2065 - Effects of HLA Mismatches on Cytokine Release Syndrome and Associated Non-Relapse Mortality in Allogeneic Stem Cell Transplantation with Post-Transplant Cyclophosphamide
Tjønnfjord, G. E.
1351 - NNV024, a Humanized Anti-CD37 Antibody with Enhanced ADCC and Extended Plasma Half-Life for the Treatment of B-Cell Malignancies
2679 - B-Cell Targeting Anti-CD37 Humanized Antibodies Engineered for Potent Effector Functions and Extended Plasma Half-Life
2857 - Gene Expression Analysis Reveals Downregulation of Complement Receptor 1 in Cold Agglutinin Disease
2679 - B-Cell Targeting Anti-CD37 Humanized Antibodies Engineered for Potent Effector Functions and Extended Plasma Half-Life
2857 - Gene Expression Analysis Reveals Downregulation of Complement Receptor 1 in Cold Agglutinin Disease
Tkachev, V.
359 - A Novel Human OX40L-CAR-Treg Specifically Targets Activated Antigen-Presenting Cells and Effectively Controls T Cell Alloreactivity and Xeno-GvHD
482 - CAR-T Cell Infusion Results in Activation of CD160+/NKG2D+/CCL5+ Non-CAR CD8+ Cytotoxic ‘Bystander’ T Cells in Both Non-Human Primates (NHP) and Patients Receiving B-Cell-Directed CAR-Ts
649 - Targeted Deletion of Activated T Cells with a Single Dose of Anti-CD137-Antibody Drug Conjugate Protects Against Acute Gvhd (AGVHD) and Promotes Tolerogenic T Cell Reconstitution after Haplo-Identical Hematopoietic Stem Cell Transplantation (HSCT)
482 - CAR-T Cell Infusion Results in Activation of CD160+/NKG2D+/CCL5+ Non-CAR CD8+ Cytotoxic ‘Bystander’ T Cells in Both Non-Human Primates (NHP) and Patients Receiving B-Cell-Directed CAR-Ts
649 - Targeted Deletion of Activated T Cells with a Single Dose of Anti-CD137-Antibody Drug Conjugate Protects Against Acute Gvhd (AGVHD) and Promotes Tolerogenic T Cell Reconstitution after Haplo-Identical Hematopoietic Stem Cell Transplantation (HSCT)
To, A.
To, C.
259 - Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7
659 - Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study
659 - Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study
To, I.
610 - Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
1630 - Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
1630 - Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
To, U.
To, Z.
1463 - Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study
2799 - Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction
2799 - Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction
Toale, K.
Toama, W.
Tobaruela, G.
Tobian, A.
Tobiasson, M.
Tobin, J.
Tobin, J. W.
Tobin, W. O.
13 - High Prevalence of Epigenetic Mutations in Histiocytic and Dendritic Cell Disorders: Results from Molecular Analysis of a Large Cohort from Histiocytosis Working Group
1738 - Mutational Profiling of Rosai-Dorfman Disease and Association with Phenotype: A Multi-Institutional Study
4374 - Efficacy of MEK Inhibitors in Erdheim Chester Disease
1738 - Mutational Profiling of Rosai-Dorfman Disease and Association with Phenotype: A Multi-Institutional Study
4374 - Efficacy of MEK Inhibitors in Erdheim Chester Disease
Tobinai, K.
Todaro, G.
Todisco, E.
62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
4048 - BCL-2 and BCL-XL Antagonists for the Treatment of Relapsed and Refractory Adult Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. a Campus ALL Real-Life Study
4048 - BCL-2 and BCL-XL Antagonists for the Treatment of Relapsed and Refractory Adult Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. a Campus ALL Real-Life Study
Todisco, E.
Todisco, G.
Tofacchi, E.
Toffoletto, B.
Tofovic, S. P.
Togami, K.
Tognoni, G.
Toiber Temin, N.
Tojo, A.
311 - Durable Clinical Impacts and Mechanisms of Action and Resistance in EZH1/2-Targeting Epigenetic Therapy
924 - Dysfunctional Clusterin-Positive Hematopoietic Stem Cells Expand with Aging
3868 - Mathematical Modeling and Analysis of Aging Alteration of Hematopoietic Stem Cell Symmetric and Asymmetric Division
924 - Dysfunctional Clusterin-Positive Hematopoietic Stem Cells Expand with Aging
3868 - Mathematical Modeling and Analysis of Aging Alteration of Hematopoietic Stem Cell Symmetric and Asymmetric Division
Tokaz, M.
Tokunaga, K.
Tolbert, J.
157 - Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
1925 - MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
1925 - MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
Toldbod, H.
Toledo, J. M.
Toledo, P.
Tolios, A.
Tolison, H.
Tollefsen, K. M.
Tomasevic, N.
Tomasian, V.
Tomasoni, C.
Tomassetti, S.
Tomasso, A.
Tomasson, M. H.
Tomasson, M. H.
Tomaszewska, A.
3448 - Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation
3648 - Hypoxia Regulates the Immunoregulatory Properties of CD71+ Erythroid Cells
3648 - Hypoxia Regulates the Immunoregulatory Properties of CD71+ Erythroid Cells
Tomazos, I.
Tomczak, L.
Tomic, K.
Tomita, A.
Tomita, M.
Tomiyama, Y.
Tomizawa, D.
605 - Evaluation of High-Dose Cytarabine Induction Therapy and Flow Cytometric Measurable Residual Disease Monitoring for Children with De Novo Acute Myeloid Leukemia: A Report from the JPLSG-AML-12 Trial
1476 - Treatment Outcomes of Childhood Picalm:MLLT10+ Acute Leukemias: An International Retrospective Study
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
4114 - Prognosis of Pediatric Acute Myeloid Leukemia with KMT2A-MLLT3 According to DNA Methylation Patterns: Jccg JPLSG AML-05 Study
1476 - Treatment Outcomes of Childhood Picalm:MLLT10+ Acute Leukemias: An International Retrospective Study
2742 - Safety and Efficacy of Arsenic Trioxide in the Treatment of Newly Diagnosed Pediatric Acute Promyelocytic Leukemia: Results from the JPLSG AML-P13 Study
4114 - Prognosis of Pediatric Acute Myeloid Leukemia with KMT2A-MLLT3 According to DNA Methylation Patterns: Jccg JPLSG AML-05 Study
Tomizawa, K.
Tomkinson, B.
64 - Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
1516 - Preclinical In Vivo Activity of the Menin Inhibitor Ziftomenib (KO-539) in Pediatric KMT2A-Rearranged Acute Lymphoblastic Leukemia
1516 - Preclinical In Vivo Activity of the Menin Inhibitor Ziftomenib (KO-539) in Pediatric KMT2A-Rearranged Acute Lymphoblastic Leukemia
Tomlinson, B.
Tommasini, T.
Tomoka, T.
Tomowiak, C.
616 - Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)
3115 - Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
3117 - A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial
3124 - Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53
3115 - Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
3117 - A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial
3124 - Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53
Tondeur, S.
Tonelli, A.
Tong, B.
Tong, E.
Tong, H.
942 - Homoharringtonine Synergizes Strongly with Venetoclax Against the Early T-Cell Progenitor Acute Lymphoblastic Leukemia：from Bench to Bed
1099 - Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Prospective, Single-Center, Single-Arm, Phase 2 Clinical Trial
1408 - Cerebrospinal Fluid Interleukin-6 Is a Potential Diagnostic Biomarker for Central Nervous System Involvement in Adult Acute Myeloid Leukemia
1450 - Venetoclax Plus “2 + 5” Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukemia: A Single-Center Retrospective Analysis
1748 - The Transcriptional Factor ONECUT3 Is a Driver and Therapeutic Target for Complex Karyotype MDS
3066 - The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway
3921 - RIPK3 Deficiency Caused By DNA Hypermethylation Blocks R-2-Hydroxyglutarate Induced Necroptosis in AML with IDH Mutation
4389 - EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes
4393 - Recombinant Human Erythropoietin Combined with All-Trans Retinoic Acid and Testosterone Undecanoate in the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes: A Multicenter, Open-Label, Prospective Trial
4402 - Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of Primary Myelodysplastic Syndrome Patients with Myelofibrosis
1099 - Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Prospective, Single-Center, Single-Arm, Phase 2 Clinical Trial
1408 - Cerebrospinal Fluid Interleukin-6 Is a Potential Diagnostic Biomarker for Central Nervous System Involvement in Adult Acute Myeloid Leukemia
1450 - Venetoclax Plus “2 + 5” Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukemia: A Single-Center Retrospective Analysis
1748 - The Transcriptional Factor ONECUT3 Is a Driver and Therapeutic Target for Complex Karyotype MDS
3066 - The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway
3921 - RIPK3 Deficiency Caused By DNA Hypermethylation Blocks R-2-Hydroxyglutarate Induced Necroptosis in AML with IDH Mutation
4389 - EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes
4393 - Recombinant Human Erythropoietin Combined with All-Trans Retinoic Acid and Testosterone Undecanoate in the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes: A Multicenter, Open-Label, Prospective Trial
4402 - Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of Primary Myelodysplastic Syndrome Patients with Myelofibrosis
Tong, H.
1603 - Tucidinostat Maintenance after Achieving Objective Response to First-Line Therapy in Peripheral T-Cell Lymphoma: A Single-Center Retrospective Case-Control Study
1759 - A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome
3974 - Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)
1759 - A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome
3974 - Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)
Tong, J.
Tong, S. Y.
Tong, W.
Tong, Y.
2059 - Metagenomic Next-Generation Sequencing for Pathogens in Bronchoalveolar Lavage Fluid Improve the Survival of Patients with Pulmonary Complications after Allogeneic Hematopoietic Stem Cell Transplantation
3394 - Phase I Study of SHR0302, a Selective JAK1 Inhibitor, Combined with Prednisone for First-Line Treatment of Chronic Graft-Versus-Host Disease after Allo-HSCT
4697 - Low-Dose Antithymocyte Globulin Plus Low-Dose Post-Transplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after Haploidentical Peripheral Blood Stem Cell Transplants: A Large Sample, Long-Term Follow-up Retrospective Study
3394 - Phase I Study of SHR0302, a Selective JAK1 Inhibitor, Combined with Prednisone for First-Line Treatment of Chronic Graft-Versus-Host Disease after Allo-HSCT
4697 - Low-Dose Antithymocyte Globulin Plus Low-Dose Post-Transplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after Haploidentical Peripheral Blood Stem Cell Transplants: A Large Sample, Long-Term Follow-up Retrospective Study
Tong, Y.
Tong, Y.
Toni, I. M.
Tonino, S.
950 - Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
2899 - Outcome of Transformed Marginal Zone Lymphoma: A Population Based Study
4153 - Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
2899 - Outcome of Transformed Marginal Zone Lymphoma: A Population Based Study
4153 - Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma
Tonseth, R. P.
Tool, A. T.
Toomey, K.
Toomey, N. L.
Topçuoğlu, P.
Topoz, I.
Topp, M. S.
51 - Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL
1368 - Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
1368 - Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
Toprak, S. K.
Torabi, A.
Torbett, B. E.
Tordi, A.
Torelli, L.
Toribio Castelló, S. M.
460 - Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial
4377 - Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?
4377 - Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?
Torka, P.
154 - Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy
170 - Impact of Monoclonal Protein at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma: A Multicenter Cohort Study
795 - Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study
1000 - Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
1669 - High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
2262 - The Age, Comorbidities and Albumin (ACA) Index Is Independently Associated with Overall Survival in Patients with Mantle Cell Lymphoma (MCL)
2267 - Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis
2881 - Evaluation of Antibody and T Cell Responses to COVID-19 Vaccination in Patients with Lymphoid Malignancies Receiving B Cell-Depleting Agents
2925 - Clinical Impact of the Intensity of Induction Regimens Prior to Consolidation in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma (PTCL)
4226 - Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival
4922 - Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy
- Should I Stay or Should I Go?
170 - Impact of Monoclonal Protein at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma: A Multicenter Cohort Study
795 - Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study
1000 - Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
1669 - High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series
2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial
2262 - The Age, Comorbidities and Albumin (ACA) Index Is Independently Associated with Overall Survival in Patients with Mantle Cell Lymphoma (MCL)
2267 - Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis
2881 - Evaluation of Antibody and T Cell Responses to COVID-19 Vaccination in Patients with Lymphoid Malignancies Receiving B Cell-Depleting Agents
2925 - Clinical Impact of the Intensity of Induction Regimens Prior to Consolidation in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma (PTCL)
4226 - Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival
4922 - Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy
- Should I Stay or Should I Go?
Tormey, C.
Tormo, M.
468 - Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes
945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
4021 - Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
4021 - Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
Törngren, M.
Toro Velez, E.
2979 - Racial and Ethnic Disparities for Diffuse Large B-Cell Lymphoma: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis with Emphasis on Hispanics
4921 - Current Status of Demographics and Survival Outcomes of Cutaneous T-Cell Lymphoma - Not Otherwise Specified in United States: A Contemporary Population Based Study with Focus on Hispanics
4921 - Current Status of Demographics and Survival Outcomes of Cutaneous T-Cell Lymphoma - Not Otherwise Specified in United States: A Contemporary Population Based Study with Focus on Hispanics
Torok, K.
3429 - Distinct Patterns in the Reconstitutions of Treg and T-Helper Subsets after Autologous Hematopoietic Stem Cell Transplantation in Juvenile-Onset Systemic Sclerosis Patients
3432 - Autologous Stem Cell Transplantation (ASCT) for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) Is Safe and Well Tolerated and Improves Clinical and Patient-Reported Outcomes
3432 - Autologous Stem Cell Transplantation (ASCT) for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) Is Safe and Well Tolerated and Improves Clinical and Patient-Reported Outcomes
Török, O.
Torok-Storb, B.
Torrance, R.
Torre, E.
Torregrosa Diaz, J. M.
Torregrosa, G.
Torrejon Guzman, N.
Torrent, A.
Torres, A.
165 - Targeting CNS Lymphoma with Intravenous Axicabtagene Ciloleucel: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site
440 - A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)
440 - A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)
Torres Cabala, C.
Torres, D.
Torres, L.
Torres, L. S.
176 - Microbial Metabolites Target Histone Deacetylases to Trigger Vascular Inflammation in Sickle Cell Disease
178 - Dietary Iron Restriction Alters Microbiota-Host Crosstalk and Protects Against Vaso-Occlusion and Organ Damage in Sickle Cell Disease Mice
3678 - P-Selectin Blockage Potentiates the Inhibiting Effects of Inflammasome Cytokine Neutralization on Leukocyte Recruitment in an In Vivo Model of Acute Sickle Cell Vaso-Occlusion
178 - Dietary Iron Restriction Alters Microbiota-Host Crosstalk and Protects Against Vaso-Occlusion and Organ Damage in Sickle Cell Disease Mice
3678 - P-Selectin Blockage Potentiates the Inhibiting Effects of Inflammasome Cytokine Neutralization on Leukocyte Recruitment in an In Vivo Model of Acute Sickle Cell Vaso-Occlusion
Torres, M.
Torres, M.
Torres, M.
Torres Viera, M. A.
2980 - Diffuse Large B-Cell Lymphoma (DLBCL) in the Elderly: Real World Experience in Latin America. A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
2985 - Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
4905 - Evolution of Treatment Patterns and Prognostic Biomarkers in Latin American Patients with Chronic Lymphocytic Leukemia: A Study By the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
2985 - Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
4905 - Evolution of Treatment Patterns and Prognostic Biomarkers in Latin American Patients with Chronic Lymphocytic Leukemia: A Study By the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
Torres, V.
3199 - Multiple Myeloma Patients Aged 40 Years and Younger Have the Same Prognosis As Older Patients in an Analysis of Real-World Evidence from Latin America: A Study of 1,316 Patients from the Gelamm Latin American Multiple Myeloma Studygroup
4042 - Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group
4042 - Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group
Torres-Almonacid, J.
Torres-Diz, M.
Torri, V.
Toscani, D.
1834 - Glutamate Metabolism Shapes Osteoclast Differentiation: New Potential Therapeutic Target to Block Osteoclastic Bone Resorption in Multiple Myeloma Patients
3005 - Identification of the Proteasome Subunits PSMB4 and PSMD4 As Novel Targets in Multiple Myeloma Patients Carrying 1q21 Amplification
3005 - Identification of the Proteasome Subunits PSMB4 and PSMD4 As Novel Targets in Multiple Myeloma Patients Carrying 1q21 Amplification
Tosi, P.
547 - Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi
751 - Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial
3088 - Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
751 - Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial
3088 - Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
Tosic, I.
Toska, S.
Toskic, D.
4515 - Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
4547 - The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients
4547 - The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients
Tosteson, A.
Tosteson, T.
Tosto, F. A.
952 - Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease
2939 - Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy
2939 - Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy
Tothova, Z.
Totiger, T. M.
45 - XPO1 Overexpression Is a Mechanism of Resistance to Eprenetapopt and 5-Azacitidine Therapy That Can be Therapeutically Exploited for the Treatment of TP53 Mutated Myeloid Malignancies
750 - Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
862 - Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
4083 - A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes
750 - Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
862 - Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
4083 - A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes
Totterdell, J.
Toubai, T.
Touloumenidou, T.
Toups, J.
Touré, A. O.
Touré, S. A.
Toure, S. A.
Tournilhac, O.
553 - Late Failure of Aggressive B-Cell Lymphoma Following CAR T-Cell Therapy: A Lysa Study from the Descar-T Registry
616 - Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)
722 - Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma
956 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”
1596 - The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study
1604 - Safety and Efficacy of Tinostamustine in Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL): Early Results from an Additional Expansion Cohort of a Phase I Study
2114 - Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
3115 - Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
3117 - A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial
616 - Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)
722 - Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma
956 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”
1596 - The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study
1604 - Safety and Efficacy of Tinostamustine in Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL): Early Results from an Additional Expansion Cohort of a Phase I Study
2114 - Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
3115 - Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation
3117 - A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial
Tousseyn, T.
Toutoudaki, K.
Touw, I. P.
Touya, M.
3621 - Real World Outcomes in Acute Myeloid Leukemia Patients Following Post Hematopoietic Stem-Cell Transplantation Maintenance Treatment with Midostaurin or Sorafenib: A US Retrospective Cohort Study
3627 - Streamline – Retrospective Cohort Study of FLT3-mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) Diagnosis
3627 - Streamline – Retrospective Cohort Study of FLT3-mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) Diagnosis
Touzeau, C.
157 - Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
159 - Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
160 - Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
161 - RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
569 - A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial
971 - Minimal Residual Disease Monitoring By Targeted Mass Spectrometry Allows Early Relapse Detection in Multiple Myeloma
1826 - TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1
1847 - Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax
1927 - Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
1939 - Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03
2035 - French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry
2680 - STP938, a Selective CTPS1 Inhibitor, Shows Single Agent Activity and Synergy with BCL2 Inhibition in Preclinical Models of Mantle Cell Lymphoma
3233 - Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
3240 - Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
3299 - Biological Differences between Axi-Cel and Tisa-Cel Products and Impacts on Outcomes in Lymphoma Patients
4491 - Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1–3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
159 - Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
160 - Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
161 - RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
569 - A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial
971 - Minimal Residual Disease Monitoring By Targeted Mass Spectrometry Allows Early Relapse Detection in Multiple Myeloma
1826 - TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1
1847 - Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax
1927 - Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
1939 - Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03
2035 - French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry
2680 - STP938, a Selective CTPS1 Inhibitor, Shows Single Agent Activity and Synergy with BCL2 Inhibition in Preclinical Models of Mantle Cell Lymphoma
3233 - Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
3240 - Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
3299 - Biological Differences between Axi-Cel and Tisa-Cel Products and Impacts on Outcomes in Lymphoma Patients
4491 - Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1–3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
Tovaglieri, N.
Tovar, N.
1892 - Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma
4619 - Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma
4648 - CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell
4619 - Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma
4648 - CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell
Tovar-Romero, H. A.
Tovy, A.
Towfic, F.
Towle, K.
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
1854 - Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability
1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
1854 - Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability
1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
Towlerton, A. M.
Towne, S. D.
Townsend Nugent, L.
Townsend, R. R.
Townsend, W.
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
1810 - First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL)
4259 - CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
4817 - CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer 89Zr-Crefmirlimab Berdoxam
1810 - First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL)
4259 - CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
4817 - CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer 89Zr-Crefmirlimab Berdoxam
Toya, T.
2053 - Novel Prediction Models of Nonrelapse Mortality in Patients Specific to Each Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Analysis from the Kanto Study Group for Cell Therapy (KSGCT)
4019 - Mutational Analysis of DNMT3A Improves the Prognostic Stratification Using NPM1/FLT3-ITD Genotypes in Patients with Acute Myeloid Leukemia
4019 - Mutational Analysis of DNMT3A Improves the Prognostic Stratification Using NPM1/FLT3-ITD Genotypes in Patients with Acute Myeloid Leukemia
Tozaki, H.
202 - CTX-712, a Novel Splicing Modulator Targeting Myeloid Neoplasms
2763 - A First-in-Human Phase I Study of CTX-712 in Patients with Advanced, Relapsed or Refractory Malignant Tumors - Hematologic Malignancies Dose Escalation Cohort
4000 - Preclinical Translational Research Suggests a Clinical Trial Strategy for a Novel MALT1 Inhibitor ONO-7018/CTX-177 Against Malignant Lymphomas
2763 - A First-in-Human Phase I Study of CTX-712 in Patients with Advanced, Relapsed or Refractory Malignant Tumors - Hematologic Malignancies Dose Escalation Cohort
4000 - Preclinical Translational Research Suggests a Clinical Trial Strategy for a Novel MALT1 Inhibitor ONO-7018/CTX-177 Against Malignant Lymphomas
Toze, C. L.
Trabut, L.
Tracy, S.
542 - Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study
3207 - Novel Transcriptomics Based Stratification Approach Using the Commpass Dataset Reveals Mechanistic Insights into Current and Upcoming MM Therapies
3207 - Novel Transcriptomics Based Stratification Approach Using the Commpass Dataset Reveals Mechanistic Insights into Current and Upcoming MM Therapies
Tracy, S. I.
Traer, E.
461 - ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients
1429 - Outcomes with Molecularly Targeted Agents As Salvage Therapy Following Frontline HMA/Venetoclax in Adults with Acute Myeloid Leukemia: A Multi-Center Retrospective Analysis
2653 - Inhibition of CDC7 with Sgr-2921 in AML Models Results in Enhanced DNA Damage and Anti-Leukemic Activity As Monotherapy and in Combination with Standard of Care Agents
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
1429 - Outcomes with Molecularly Targeted Agents As Salvage Therapy Following Frontline HMA/Venetoclax in Adults with Acute Myeloid Leukemia: A Multi-Center Retrospective Analysis
2653 - Inhibition of CDC7 with Sgr-2921 in AML Models Results in Enhanced DNA Damage and Anti-Leukemic Activity As Monotherapy and in Combination with Standard of Care Agents
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
Traets, M. J.
Traina, F.
Tramontano, A. C.
Tran, B.
Tran, Jr., D. Q.
510 - Racial/Ethnic Disparities in Hemophilia-Related Distress
2469 - Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1
3573 - Sex-Differences in Distress, Quality of Life, and Depression Among People with Hemophilia
2469 - Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1
3573 - Sex-Differences in Distress, Quality of Life, and Depression Among People with Hemophilia
Tran, E.
933 - Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax
4120 - Multiomic Single-Cell Sequencing of Mixed Phenotypic Acute Leukemia (MPAL) Reveals Complex Immunophenotypic, Transcriptional, and Genetic Heterogeneity
4120 - Multiomic Single-Cell Sequencing of Mixed Phenotypic Acute Leukemia (MPAL) Reveals Complex Immunophenotypic, Transcriptional, and Genetic Heterogeneity
Tran, E. N.
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
Tran, H.
133 - Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19
686 - Endothelial Cell Activation Enhances Thromboinflammation in Vitt
783 - Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011
1157 - Health-Related Quality of Life in Patients with Hemophilia A or B with Inhibitors on Concizumab Prophylaxis: Results from the Phase 3 explorer7 Study
2494 - The Clinicalpathological Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Following ChAdOx1 (AstraZeneca AZD1222) Vaccination and Case Outcomes in Australia
4779 - The Effects of Immunomodulation with Corticosteroids to Manage an AAV Capsid Immune response in the Phase I/II Study of SPK-8011
4783 - Rapid Clearance of Vector Following AAV-Mediated FVIII Gene Transfer in the Phase I/II Trial of SPK-8011 in People with Hemophilia A
686 - Endothelial Cell Activation Enhances Thromboinflammation in Vitt
783 - Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011
1157 - Health-Related Quality of Life in Patients with Hemophilia A or B with Inhibitors on Concizumab Prophylaxis: Results from the Phase 3 explorer7 Study
2494 - The Clinicalpathological Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Following ChAdOx1 (AstraZeneca AZD1222) Vaccination and Case Outcomes in Australia
4779 - The Effects of Immunomodulation with Corticosteroids to Manage an AAV Capsid Immune response in the Phase I/II Study of SPK-8011
4783 - Rapid Clearance of Vector Following AAV-Mediated FVIII Gene Transfer in the Phase I/II Trial of SPK-8011 in People with Hemophilia A
Tran, J. N.
Tran, L.
Tran, N.
3236 - Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
4563 - Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius
4563 - Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Aquarius
Tran, Q.
436 - Subtype Dependent Drug Resistance Alterations in Relapsed Childhood B-ALL: A Children’s Oncology Group Study
1472 - Clinical and Functional Implications of MYC Variants As a New Class of Pathogenic Variants in AML
2801 - Pathogenic TP53 mutations Are Associated with a Poor Prognosis in De Novo AML
3906 - Tracking Clonal Evolution in Pediatric AML
1472 - Clinical and Functional Implications of MYC Variants As a New Class of Pathogenic Variants in AML
2801 - Pathogenic TP53 mutations Are Associated with a Poor Prognosis in De Novo AML
3906 - Tracking Clonal Evolution in Pediatric AML
Tran, T. H.
Tran, T.
Tran, V.
Tran, V.
Tranberg, A.
Trancucci, D.
97 - Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC‑1
1911 - Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma
1911 - Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma
Trani, L.
Trankle, B.
Trapnell, C.
Trask, N.
Trastulli, F.
Trautmann-Grill, K.
729 - Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
Travaglino, E.
Travassos, L. C.
Traverse-Glehen, A.
721 - DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features
722 - Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma
4186 - Molecular and Functional Profiling of Microenvironmental Interactions in Splenic Marginal Zone Lymphoma
722 - Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma
4186 - Molecular and Functional Profiling of Microenvironmental Interactions in Splenic Marginal Zone Lymphoma
Travis, M.
Trawinska, M. M.
621 - Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry
1706 - Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A “Campus CML” Study
4356 - Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events
4371 - Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The “RAMP” Multicenter Prospective Study
1706 - Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A “Campus CML” Study
4356 - Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events
4371 - Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The “RAMP” Multicenter Prospective Study
Treaba, D. O.
Treadwell, M.
1074 - Baseline Patient and Provider Reports of Quality of Care and Confidence Providing ED Management of Vaso-Occlusive Episodes
1082 - Mortality in Adults with Sickle Cell Disease: Results from the Sickle Cell Disease Implementation Consortium (SCDIC) Registry
3523 - A New Phen X Collection: Sickle Cell Disease Psychosocial and Social Determinants of Health Protocols
4877 - Optimizing Shared Decision Making about Hydroxyurea in Young Children with Sickle Cell Anemia
1082 - Mortality in Adults with Sickle Cell Disease: Results from the Sickle Cell Disease Implementation Consortium (SCDIC) Registry
3523 - A New Phen X Collection: Sickle Cell Disease Psychosocial and Social Determinants of Health Protocols
4877 - Optimizing Shared Decision Making about Hydroxyurea in Young Children with Sickle Cell Anemia
Tredicine, M.
Treece, A.
Tregnago, C.
Trelles-Martínez, R.
Tremblay, C.
Tremblay, D.
Tremblay-Lemay, R.
Trentin, L.
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
3131 - Continuous Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia and TP53 Abnormalities. a Study of the Italian Campus CLL
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
3131 - Continuous Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia and TP53 Abnormalities. a Study of the Italian Campus CLL
Treon, S. P.
231 - Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
641 - The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström’s Macroglobulinemia
723 - Multi-Omic Analysis of 253 Untreated Patients with Waldenström’s Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression
1538 - Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom’s Macroglobulinemia
2896 - Skin Punch Biopsy Findings in Patients with IgM MGUS and Waldenström Macroglobulinemia Presenting with Peripheral Neuropathy
4535 - Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
641 - The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström’s Macroglobulinemia
723 - Multi-Omic Analysis of 253 Untreated Patients with Waldenström’s Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression
1538 - Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom’s Macroglobulinemia
2896 - Skin Punch Biopsy Findings in Patients with IgM MGUS and Waldenström Macroglobulinemia Presenting with Peripheral Neuropathy
4535 - Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
Trespidi, L.
Treusch, S.
Trevisani, C.
Triantafillou, M.
Triantafyllou, T.
1913 - Improved Survival of Patients with Primary Plasma Cell Leukemia with VRD or Daratumumab-Based Quadruplets: A Multicenter Study By the Greek Myeloma Study Group
4299 - Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era
4299 - Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era
Tricarico, S.
Triche, T.
Triche, Jr., T. J.
Trickett, A.
Tricot, G.
Tricot, S.
956 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”
1575 - Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)
1575 - Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)
Tricta, F.
Tridandapani, S.
Triebwasser, M.
Triguero, A.
623 - Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study
4712 - Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic Graft vs. Host Disease: A Report of Two Phase I/II Trials
4712 - Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic Graft vs. Host Disease: A Report of Two Phase I/II Trials
Trikha, R.
Trikha, R.
1251 - Terminal Complement Inhibition and Control of Hemolysis in Paroxysmal Nocturnal Hemoglobinuria Following Switching from High-Dose Eculizumab to Ravulizumab: An Interim Analysis
2566 - Treatment Outcomes of Complement Protein C5 Inhibition in 509 Patients with Paroxysmal Nocturnal Hemoglobinuria in the United Kingdom
2566 - Treatment Outcomes of Complement Protein C5 Inhibition in 509 Patients with Paroxysmal Nocturnal Hemoglobinuria in the United Kingdom
Trimbur, C.
Tringale, K. R.
557 - Initial Treatment Response Is Prognostic and Predictive of Relapse Patterns: Outcomes of >500 Patients Treated for Primary CNS Lymphoma
1573 - “Big Boom” (4 Gy x 1) Radiation Treatment (RT) Versus “Big Boom” (2 Gy x 2) for Non-Hodgkin Lymphoma (NHL)
2854 - Genetic Alterations of Crebbp Are Associated with Radiosensitivity in Follicular Lymphoma
2974 - Radiotherapy for Secondary CNS Lymphoma: Patterns of Utilization and Clinical Outcomes
4292 - Safety and Efficacy of Splenic Irradiation for Non-Hodgkin Lymphoma
1573 - “Big Boom” (4 Gy x 1) Radiation Treatment (RT) Versus “Big Boom” (2 Gy x 2) for Non-Hodgkin Lymphoma (NHL)
2854 - Genetic Alterations of Crebbp Are Associated with Radiosensitivity in Follicular Lymphoma
2974 - Radiotherapy for Secondary CNS Lymphoma: Patterns of Utilization and Clinical Outcomes
4292 - Safety and Efficacy of Splenic Irradiation for Non-Hodgkin Lymphoma
Trinh, I. V.
Trinkner, P.
Trinks, N.
Triplett, B. M.
Triplett, S.
Tritschler, T.
Triviño, J. C.
Trka, J.
438 - A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups
1242 - Restored Biosynthetic Pathways Induced By MSCs Serve As Rescue Mechanism in Leukemia Cells after L-Asparaginase Therapy
1413 - Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial
4136 - BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease
1242 - Restored Biosynthetic Pathways Induced By MSCs Serve As Rescue Mechanism in Leukemia Cells after L-Asparaginase Therapy
1413 - Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial
4136 - BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease
Trněný, M.
74 - Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma
1344 - Inhibition of MAPK-ERK Signaling Pathway Overcomes Microrna-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma
2852 - Sequencing-Based Analysis of Clonal Evolution of 25 Mantle Cell Lymphoma Patients at Diagnosis and after Failure of Standard Immunochemotherapy
1344 - Inhibition of MAPK-ERK Signaling Pathway Overcomes Microrna-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma
2852 - Sequencing-Based Analysis of Clonal Evolution of 25 Mantle Cell Lymphoma Patients at Diagnosis and after Failure of Standard Immunochemotherapy
Trneny, M.
1 - Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network
230 - Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R2) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
542 - Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study
953 - FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
1619 - First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R‑CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
1639 - How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?
1665 - Survival of Patients with Primary Mediastinal B-Cell Lymphoma Treated By Immunochemotherapy with or without Radiotherapy
2671 - Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma
2947 - Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma
230 - Five-Year Results and Overall Survival Update from the Phase 3 Randomized Study Augment: Lenalidomide Plus Rituximab (R2) Vs Rituximab Plus Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
542 - Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study
953 - FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
1619 - First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R‑CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
1639 - How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?
1665 - Survival of Patients with Primary Mediastinal B-Cell Lymphoma Treated By Immunochemotherapy with or without Radiotherapy
2671 - Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib Synergizes with BH3-Mimetics in Experimental Models of Relapsed/Refractory Mantle Cell Lymphoma
2947 - Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma
Trněný, M.
2840 - BCL-XL Blockage with A1155463 Significantly Increases Efficacy of Venetoclax in Mantle Cell Lymphoma in Vitro and In Vivo
2949 - Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
2949 - Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX Study
Trociukas, I.
Trøen, G.
Trojani, A.
Tromberg, B. J.
Troske, D.
3216 - Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa
4495 - Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race
4538 - Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study
4495 - Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race
4538 - Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study
Trotman, J.
315 - Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy
613 - Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network
2883 - Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study
613 - Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network
2883 - Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study
Trotta, G.
Trottier, C. A.
Trowbridge, J. J. J.
526 - Bone Marrow Stromal Cell Senescence Induced By Dnmt3a-Mutant Hematopoietic Stem and Progenitor Cells Accelerates Clonal Hematopoiesis and Progression to Leukemia
1222 - Robust Mitochondrial Metabolism Provides a Fitness Advantage to Dnmt3a-Mutant Hematopoietic Stem Cells in the Context of Aging
4100 - Metallothionein 1 (MT1) Is Selectively Required for DNMT3A;NPM1-Mutant Acute Myeloid Leukemia Proliferation
1222 - Robust Mitochondrial Metabolism Provides a Fitness Advantage to Dnmt3a-Mutant Hematopoietic Stem Cells in the Context of Aging
4100 - Metallothionein 1 (MT1) Is Selectively Required for DNMT3A;NPM1-Mutant Acute Myeloid Leukemia Proliferation
Troy, J. D.
Troyanov, S.
Trsová, I.
1742 - Upregulation of ZEB1-Derived Circular RNAs Is Associated with SF3B1-Mutated Myelodysplastic Neoplasms
1749 - Aging-Related Gene Expression Signatures Define Likelihood of Disease Progression in Patients with Lower-Risk Myelodysplastic Syndromes
1783 - Risk Assessment in Patients with Myelodysplastic Neoplasms Using the Molecular International Prognostic Scoring System: A Single-Center Study from the Czech Republic
1749 - Aging-Related Gene Expression Signatures Define Likelihood of Disease Progression in Patients with Lower-Risk Myelodysplastic Syndromes
1783 - Risk Assessment in Patients with Myelodysplastic Neoplasms Using the Molecular International Prognostic Scoring System: A Single-Center Study from the Czech Republic
Truchan, M.
Trudel, S.
158 - Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma
567 - Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity
568 - Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
1898 - Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma
1921 - Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort
1924 - Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
3243 - MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody
3248 - Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma
- Antibodies and Bispecifics for Multiple Myeloma: Effective Effector Therapy
567 - Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity
568 - Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
1898 - Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma
1921 - Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort
1924 - Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
3243 - MonumenTAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody
3248 - Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma
- Antibodies and Bispecifics for Multiple Myeloma: Effective Effector Therapy
Trudel, S.
Truger, M.
1839 - Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
1860 - Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling
2166 - Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment
3486 - How Whole Genome and Transcriptome Sequencing (WGTS) Can Contribute to Unsolved Cases in Hematology That Have Undergone Extensive Standard Diagnostic Workup: A Prospective Head-to-Head Study
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
1860 - Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling
2166 - Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment
3486 - How Whole Genome and Transcriptome Sequencing (WGTS) Can Contribute to Unsolved Cases in Hematology That Have Undergone Extensive Standard Diagnostic Workup: A Prospective Head-to-Head Study
Trujillo-Ocampo, A.
Trummer, A.
Trumpp, A.
836 - Macs - a Leukemic Stem Cell- Based Predictor of Clinical Response to Venetoclax and Other BH3 Mimetics for Acute Myeloid Leukemia
3864 - Frequent Whole Blood Donations Select for DNMT3A variants Mediating Enhanced Response to Erythropoietin
4132 - Exploring Genetic and Non-Genetic Changes Driving Tumor Evolution in CK-AML at Single-Cell Resolution
3864 - Frequent Whole Blood Donations Select for DNMT3A variants Mediating Enhanced Response to Erythropoietin
4132 - Exploring Genetic and Non-Genetic Changes Driving Tumor Evolution in CK-AML at Single-Cell Resolution
Truong, B.
Truong, B.
Truong, T.
Truong, T. H.
Truppel-Hartmann, A.
361 - KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation
3314 - KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation
3314 - KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation
Truslow, S.
Truxall, J.
Tsagkaraki, I.
Tsai, C. H.
Tsai, C.
Tsai, D.
Tsai, D. E.
229 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Tsai, H. L.
2058 - Allogeneic Blood or Marrow Transplantation (alloBMT) Using Haploidentical Grandchildren Donors and Post-Transplant Cyclophosphamide (PTCy) -Based Gvhd Prophylaxis
2101 - Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)
3442 - Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers
2101 - Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)
3442 - Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers
Tsai, J. M.
Tsai, N. C.
318 - Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2104 - Challenges of Maintenance Tyrosine Kinase Inhibitor Therapy after Allogeneic Hematopoietic Cell Transplantation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
3381 - Renal Impairment Adversely Impacts Melphalan-Induced Severe GvHD- and GI Toxicity- Free Survival (MGTFS) in Patients Undergoing Reduced Intensity Allogeneic Peripheral Blood Stem Cell Transplantation
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation
4741 - Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Tsai, R. C.
Tsai, S.
Tsai, S. (. H.
Tsai, S. B.
Tsakmaklis, N.
231 - Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
641 - The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström’s Macroglobulinemia
723 - Multi-Omic Analysis of 253 Untreated Patients with Waldenström’s Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression
1538 - Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom’s Macroglobulinemia
641 - The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström’s Macroglobulinemia
723 - Multi-Omic Analysis of 253 Untreated Patients with Waldenström’s Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression
1538 - Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom’s Macroglobulinemia
Tsaknakis, G.
Tsang, H. C.
Tsang, R.
Tsang, R.
Tschan, M. P.
2613 - Non-Glycolytic Role of the Myeloid Hexokinase 3 (HK3) in Therapy Responses of Myeloid Malignancies
3935 - The Transcription Factor PU.1 Controls Alternative Splicing of Cflip By Binding to SRSF2/10 Splice Factors in AML Therapy Responses
4187 - ULK1 Blockade Preferentially Targets Germinal Centre B-Cell – Diffuse Large B-Cell Lymphoma Subtype By Attenuating Autophagy, c-MYC and Inflammation
3935 - The Transcription Factor PU.1 Controls Alternative Splicing of Cflip By Binding to SRSF2/10 Splice Factors in AML Therapy Responses
4187 - ULK1 Blockade Preferentially Targets Germinal Centre B-Cell – Diffuse Large B-Cell Lymphoma Subtype By Attenuating Autophagy, c-MYC and Inflammation
Tse, B.
Tse, E.
1255 - Intensive Pegcetacoplan Dosing in the Management of Acute Hemolysis As Part of the 307 Open-Label Extension Study
1520 - Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma
1546 - Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome
1520 - Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma
1546 - Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome
Tse, W.
Tseng, C. H.
Tseng, C. Y.
Tseng, C. C.
2338 - ALK2 Inhibition and a Modified Activin Receptor Type Iia Ligand Trap Cotherapy Maximized Hematologic Improvements in a Mouse Model of Anemia of Inflammation
4387 - Rker-050, a Novel Activin Receptor Type II Ligand Trap, Rescued Anemia and Reduced Bone Loss in a Mouse Model of Myelodysplastic Syndromes
4387 - Rker-050, a Novel Activin Receptor Type II Ligand Trap, Rescued Anemia and Reduced Bone Loss in a Mouse Model of Myelodysplastic Syndromes
Tseng, L. J.
Tseng, M. H.
Tseng, Y. D.
2913 - Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume
4897 - Multi-Institutional Review of Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas
4897 - Multi-Institutional Review of Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas
Tseng, Y. J.
Tshernichovsy, D.
Tsingos, E.
Tsirigos, A.
Tsirigotis, P.
Tsirogianni, M.
Tsitsilonis, O. E.
Tsomo, T.
Tsou, K.
Tsuchiya, K.
Tsudama, E.
Tsui, D. W.
Tsui, H.
Tsuji, J.
102 - Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
354 - Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
354 - Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells
Tsuji, N.
Tsujimoto, S. I.
605 - Evaluation of High-Dose Cytarabine Induction Therapy and Flow Cytometric Measurable Residual Disease Monitoring for Children with De Novo Acute Myeloid Leukemia: A Report from the JPLSG-AML-12 Trial
2706 - Prognostic Factors in Children with Acute Myeloid Leukemia Receiving the First Hematopoietic Stem Cell Transplantation in Second Remission
2706 - Prognostic Factors in Children with Acute Myeloid Leukemia Receiving the First Hematopoietic Stem Cell Transplantation in Second Remission
Tsujimura, H.
Tsukamoto, S.
Tsukamoto, S.
1846 - Exhausted T Cells Characterized By Upregulation of Specific Transcription Factors Are Increased in a Mouse Model of De Novo Mature B Cell Neoplasms
2053 - Novel Prediction Models of Nonrelapse Mortality in Patients Specific to Each Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Analysis from the Kanto Study Group for Cell Therapy (KSGCT)
2053 - Novel Prediction Models of Nonrelapse Mortality in Patients Specific to Each Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Analysis from the Kanto Study Group for Cell Therapy (KSGCT)
Tsukamoto, T.
Tsukasaki, K.
959 - Oral Azacytidine in Patients with Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: Final Analysis of the Oracle Phase III Study
1570 - Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma
1614 - Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)
1570 - Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma
1614 - Interim PET-Guided ABVD or ABVD/Escalated BEACOPP for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma (JCOG1305, INNOVATE-HL study)
Tsukita, S.
Tsukune, Y.
Tsushima, T.
Tsutsumi, S.
Tsutsumi, Y.
1390 - Clinical Features of Complex Karyotype in Newly Diagnosed Acute Myeloid Leukemia
4036 - Prognostic Impact of CEBPA bZIP Domain Mutation in Cytogenetically Normal Acute Myeloid Leukemia
4095 - Subclinical Minute FLT3-ITD Clone Can be Detected in Clinically FLT3-ITD-Negative Acute Myeloid Leukemia
4150 - Better Prognosis of Dominant-Negative Type of IKZF1 Deletion in BCR-ABL-positive Adult B-Cell Acute Lymphoblastic Leukemia
4036 - Prognostic Impact of CEBPA bZIP Domain Mutation in Cytogenetically Normal Acute Myeloid Leukemia
4095 - Subclinical Minute FLT3-ITD Clone Can be Detected in Clinically FLT3-ITD-Negative Acute Myeloid Leukemia
4150 - Better Prognosis of Dominant-Negative Type of IKZF1 Deletion in BCR-ABL-positive Adult B-Cell Acute Lymphoblastic Leukemia
Tsvetkov, L.
Tu, F.
2537 - Loss of DHX15 Function Impairs Hematopoiesis in Vav-Dhx15-KO Mice and Cause DNA Damage-Induced Cell Cycle Arrest and Apoptosis in Leukemia Cell Lines
3731 - Recombinant Mouse GM-CSF Enhances the Bactericidal Ability of Pmns and Improves the Prognosis of Secondary Pseudomonas Aeruginosa Pneumonia By Intracellular IL-1β
3731 - Recombinant Mouse GM-CSF Enhances the Bactericidal Ability of Pmns and Improves the Prognosis of Secondary Pseudomonas Aeruginosa Pneumonia By Intracellular IL-1β
Tu, J. W.
Tu, N.
Tu, X.
Tu, Y.
Tubman, V. N.
Tuc, E.
Tucci, A.
233 - Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study
471 - Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy
733 - PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)
2014 - Lava-051, a Novel Bispecific Gamma-Delta T-Cell Engager (Gammabody), in Relapsed/Refractory MM and CLL: Pharmacodynamic and Early Clinical Data
2972 - Ibrutinib Alone or in Combination with R-CHOP Chemoimmunotherapy in Relapsed or Refractory Primary Central Nervous System Lymphoma (rrPCNSL): A «Real-Life» Study
3055 - Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: Role of Disease Status and Chimerism on Long-Term Outcomes
4346 - BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study
471 - Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy
733 - PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)
2014 - Lava-051, a Novel Bispecific Gamma-Delta T-Cell Engager (Gammabody), in Relapsed/Refractory MM and CLL: Pharmacodynamic and Early Clinical Data
2972 - Ibrutinib Alone or in Combination with R-CHOP Chemoimmunotherapy in Relapsed or Refractory Primary Central Nervous System Lymphoma (rrPCNSL): A «Real-Life» Study
3055 - Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: Role of Disease Status and Chimerism on Long-Term Outcomes
4346 - BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study
Tucci, F.
Tuchman, S. A.
380 - "If You Don’t Trust Your Doctor That Much...You’d Feel Less Confident Doing a Research Study": Factors Influencing Black Patient Participation in Hematology Trials
383 - "You Have Your Knowledge, but I Have My Knowledge of My Body": The Hematologist-Patient Relationship and Enrollment of Black Participants in Clinical Trials
1919 - A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell–Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma
2288 - Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy
4515 - Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
4516 - Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma
4547 - The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients
383 - "You Have Your Knowledge, but I Have My Knowledge of My Body": The Hematologist-Patient Relationship and Enrollment of Black Participants in Clinical Trials
1919 - A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell–Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma
2288 - Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy
4515 - Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
4516 - Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma
4547 - The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients
Tuck, D. P.
Tucker, A.
Tucker, A.
Tucker, D.
949 - Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1–3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
1730 - The Use of Avapritinib in Advanced Systemic Mastocytosis: Report of an Open-Label Compassionate Use Program in the United Kingdom
1810 - First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL)
1730 - The Use of Avapritinib in Advanced Systemic Mastocytosis: Report of an Open-Label Compassionate Use Program in the United Kingdom
1810 - First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL)
Tucker, E. I.
Tucker, T.
Tucker, T.
Tuddenham, E.
Tueur, G.
Tuglular, T.
4299 - Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era
4569 - Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)
4569 - Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)
Tugnait, M.
Tugolukova, E. A.
Tuinhof, I.
Tukachinsky, H.
Tuller, S.
Tulstrup, M.
Tumewu, T.
1829 - Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia
3364 - Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes – No Association of Clonal Hematopoiesis (CH) with Manufacturing Success
3364 - Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes – No Association of Clonal Hematopoiesis (CH) with Manufacturing Success
Tumula, P. K.
Tun, A. M.
Tun, H. W.
4235 - Clinical Characteristics, Survival Outcomes, and Prognostic Factors in Primary Cutaneous CD30+ T-Cell Lymphoma: National Cancer Database Analysis (2004-2018)
4238 - Clinical Characteristics, Survival Outcomes, and Prognostic Factors in Lymphocyte-Depleted Hodgkin’s Lymphoma: National Cancer Database Analysis (2004-2018)
4238 - Clinical Characteristics, Survival Outcomes, and Prognostic Factors in Lymphocyte-Depleted Hodgkin’s Lymphoma: National Cancer Database Analysis (2004-2018)
Tundwal, K.
Tuohy, E.
Tupper, C.
Turcotte, E.
Turcotte, L. M.
Turhan, A. G.
1684 - The Anti-HIV Drug Nelfinavir Exhibits Synergistic Activity with Tyrosine Kinase Inhibitors and Circumvents TKI-Resistance Conferred By T315I-Mutated BCR-ABL
3016 - Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" in Patients with TKI-Resistant or Intolerant CML
3016 - Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" in Patients with TKI-Resistant or Intolerant CML
Turi, M.
Turk, E.
1083 - Inpatient Outcomes and 30-Day Unplanned Readmissions after Cholecystectomy in Sickle Cell Patients
2696 - A Nationwide Analysis of Clinical Outcomes and Baseline Characteristics in Patients Admitted with ALL and Prior Malignancy
4032 - Demographic Characteristics and Outcomes in Patients with AML and Previous Diagnosis of CML or MDS
4283 - Trends in Inpatient Immunotherapy for Lymphoma: The Impact of CAR T-Cell Therapy
2696 - A Nationwide Analysis of Clinical Outcomes and Baseline Characteristics in Patients Admitted with ALL and Prior Malignancy
4032 - Demographic Characteristics and Outcomes in Patients with AML and Previous Diagnosis of CML or MDS
4283 - Trends in Inpatient Immunotherapy for Lymphoma: The Impact of CAR T-Cell Therapy
Turkalj, S.
493 - Genotyping of Multiple Genomic Loci with Chromatin Accessibility Profiling in Single Cells Links Clonal Hierarchy with Epigenetic Variation in Acute Myeloid Leukemia
925 - Single-Cell Analysis of Human Clonal Hematopoiesis Identifies Distinct Impact of DNMT3A and TET2 mutations on Hematopoietic Differentiation
925 - Single-Cell Analysis of Human Clonal Hematopoiesis Identifies Distinct Impact of DNMT3A and TET2 mutations on Hematopoietic Differentiation
Turki, A. T.
227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
2834 - Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration
2834 - Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance
Turkina, A. G.
80 - Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA
620 - Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
621 - Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
4334 - ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors
4342 - Two-Year Updated Results of Asciminib Managed-Access Program (MAP) in Russia
620 - Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib
621 - Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry
3009 - Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
4334 - ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors
4342 - Two-Year Updated Results of Asciminib Managed-Access Program (MAP) in Russia
Turlure, P.
50 - In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival – Results from the Graall-2014 Trial
303 - Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
4413 - Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351
303 - Prognostic Impact of Monoallelic Versus Biallelic TP53 Alterations in Intensively-Treated Adults AML Patients: A Retrospective Study from the ALFA Group
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
4413 - Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351
Turna, A.
Turner, A. P.
Turner, B.
Turner, D. C.
1628 - Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
2871 - Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study
2871 - Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study
Turner, R.
Turner, S.
Turpuseema, T.
Turrentine, K. B.
Turrini, M.
3088 - Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
4079 - Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results
4079 - Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results
Turroni, S.
Turtle, C. J.
656 - Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
2024 - Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)
2025 - Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)
3316 - Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
3335 - A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
4652 - Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
4653 - Efficacy and Safety of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder in Adults with Relapsed/Refractory B-ALL
4654 - CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study
2024 - Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)
2025 - Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)
3316 - Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
3335 - A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
4652 - Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies
4653 - Efficacy and Safety of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder in Adults with Relapsed/Refractory B-ALL
4654 - CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study
Tuscano, J. M.
232 - Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)
2764 - A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia
3205 - Assessing Time to Diagnosis, End-Organ Damage and Treatment Response in Young Newly Diagnosed Multiple Myeloma Patients
3538 - Identifying Multiple Myeloma Patients Using Automated Data Capture from Electronic Medical Records
4024 - Healthcare Resource Utilization in Acute Myeloid Leukemia Treatments: Hypomethylating Agent + Venetoclax Vs. High Intensity Regimens
4252 - A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses
2764 - A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia
3205 - Assessing Time to Diagnosis, End-Organ Damage and Treatment Response in Young Newly Diagnosed Multiple Myeloma Patients
3538 - Identifying Multiple Myeloma Patients Using Automated Data Capture from Electronic Medical Records
4024 - Healthcare Resource Utilization in Acute Myeloid Leukemia Treatments: Hypomethylating Agent + Venetoclax Vs. High Intensity Regimens
4252 - A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses
Tušková, L.
Tvrdik, T.
Twickler, I.
Tyagi, A.
Tyagi, M.
Tyavanagimatt, S.
Tychhon, B.
Tyekucheva, S.
Tyekucheva, S.
344 - Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
3128 - Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia
4433 - Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)
3128 - Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia
4433 - Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)
Tylee, K. L.
Tyler, P. D.
Tyner, J. W.
427 - Defining Clinical and Molecular Biomarkers for Venetoclax-Based Drug Combinations to Augment AML Therapy
862 - Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
1324 - The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist
2681 - Targeting Sumoylation with Subasumstat (TAK-981), a Selective Inhibitor of SUMO-Activating Enzyme (SAE), Induces Mitochondrial Dysfunction in Preclinical Models of Non-Hodgkin Lymphoma (NHL)
3953 - Characterize Biomarkers and Mechanisms of Resistance for MDM2 Inhibitors in AML
4794 - Mouse Model of Combination Targeted Therapy in PTPN11 Driven Leukemia
862 - Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
1324 - The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist
2681 - Targeting Sumoylation with Subasumstat (TAK-981), a Selective Inhibitor of SUMO-Activating Enzyme (SAE), Induces Mitochondrial Dysfunction in Preclinical Models of Non-Hodgkin Lymphoma (NHL)
3953 - Characterize Biomarkers and Mechanisms of Resistance for MDM2 Inhibitors in AML
4794 - Mouse Model of Combination Targeted Therapy in PTPN11 Driven Leukemia
Tzachanis, D.
714 - Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)
4667 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
4667 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Tzachanis, D.
1368 - Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
1932 - Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/Refractory Multiple Myeloma
1932 - Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/Refractory Multiple Myeloma
Tzannoudaki, M.
Tzoran, I.
316 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti–PD-1 Treatment
2907 - Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia
2907 - Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia